mirabegron profile

mirabegron: a beta3-adrenergic receptor agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mirabegron : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-amino-1,3-thiazol-4-ylacetic acid with the anilino group of (1R)-2-{[2-(4-aminophenyl)ethyl]amino}-1-phenylethanol. Used for the treatment of overactive bladder syndrome. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	9865528
CHEMBL ID	2095212
CHEBI ID	65349
SCHEMBL ID	904788
MeSH ID	M0510156

Synonym
HY-14773
D09535
223673-61-8
mirabegron (usan/jan)
myrbetriq (tn)
2-amino-n-[4-[2-[[(2r)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-thiazoleacetamide
ym 178;2-(2-aminothiazol-4-yl)-n-[4-[2-[[(2r)-2-hydroxy-2-phenyl-ethyl]amino]ethyl]phenyl]acetamide
A816162
2-(2-aminothiazol-4-yl)-4'-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)acetanilide
betanis
ym 178
myrbetriq
4-thiazoleacetamide, 2-amino-n-(4-(2-(((2r)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)-
unii-mvr3jl3b2v
ym178
ym-178
mirabegron
mirabegron [usan:inn]
mvr3jl3b2v ,
betmiga
CHEMBL2095212
S4009
mirabegron [jan]
mirabegron [inn]
2-(2-amino-1,3-thiazol-4-yl)-n-(4-(2-(((2r)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)acetamide
mirabegron [mi]
mirabegron [usan]
mirabegron [mart.]
mirabegron [vandf]
mirabegron [who-dd]
2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
mirabegron [orange book]
CS-0915
CHEBI:65349 ,
2-(2-amino-1,3-thiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
AKOS016340341
2-(2-amino-1,3-thiazol-4-yl)-n-[4-[2-[[(2r)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide
gtpl7445
DB08893
KS-1398
(r)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide
PBAPPPCECJKMCM-IBGZPJMESA-N
SCHEMBL904788
mirabegron (ym178)
(r)-2-(2-aminothiazol-4-yl)-n-(4-(2-(2-hydroxy-2-phenylethylamino)ethyl)phenyl)acetamide
(r)-2-(2-aminothiazol-4-yl)-n-(4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)acetamide
AB01565808_02
2-(2-amino-1,3-thiazol-4-yl)-n-(4-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}phenyl)acetamide
EX-A1050
mfcd11100356
HMS3714I09
SW220301-1
Q3702534
Z1980444597
AMY1800
AR-270/43507997
HMS3885M16
CCG-268611
NCGC00386239-01
2-(2-azanyl-1,3-thiazol-4-yl)-n-[4-[2-[[(2r)-2-oxidanyl-2-phenyl-ethyl]amino]ethyl]phenyl]ethanamide
h6u ,
DTXSID101021648
g04bd12
mirabegron (mart.)
2-(2-aminothiazol-4-yl)-n-(4-(2-(((2r)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)acetamide
mirabegronum
2-(2-aminothiazol-4-yl)-n-(4-(2-(((2r)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl) acetamide
myrbetriq granules

Excerpt	Reference	Relevance
"Mirabegron is a promising drug to control OAB symptoms in patients with PD with an excellent safety profile."	( The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial. Chakra, MA; Dabboucy, B; Dellis, A; Fares, Y; Moussa, M; Papatsoris, A, 2022)	2.45
"Mirabegron is a first-generation β3AR agonist that is effective for frequency, urgency urinary incontinence (UUI) and urgency, but has interactions with cytochrome P450 enzymes (CYPs) and cardiovascular sequelae."	( Vibegron for the treatment of overactive bladder: a comprehensive update. Dmochowski, R; Gleicher, S; Reynolds, WS; Sebesta, EM, 2022)	1.44
"Mirabegron is a new drug acting by the ß3-adrenoceptor agonism."	( Cost-effectiveness evaluation of mirabegron versus anti-muscarinics and third-line therapies: a systematic review. Azadmehr, B; Mohammadnezhad, G; Yousefi, N, 2022)	1.72
"Mirabegron is a selective beta-3 adrenergic receptor (β-3 AR) agonist used to treat an overactive bladder."	( Mirabegron alleviates acetic acid-induced colitis in rats: Role of adiponectin and GSTM1/GSH detoxification pathway. Abed El Baky, MF; Hafez, HM; Mohamed, MZ; Mokhemer, SA, 2023)	3.07
"Mirabegron is a beta-3 adrenergic receptor agonist that received FDA approval in 2021 to treat neurogenic detrusor overactivity (NDO) in children ages three years and older. "	( Cost analysis for mirabegron use in the treatment of children with neurogenic bladder. Balthazar, A; Estrada, C; Sherlock, R; Xu, R, 2023)	2.69
"Mirabegron appears to be an effective treatment in the management of neurogenic bladder unresponsive to antimuscarinics, particularly in patients presenting with storage symptoms. "	( The use of mirabegron in neurogenic bladder: a systematic review. Abi Tayeh, G; Chebel, R; El Helou, E; El Helou, J; Jalkh, G; Labaki, C; Nemr, E, 2020)	2.39
"Mirabegron is a β3-agonist drug approved by the FDA for use in 2012 and administered in overactive bladder. "	( Effect of Mirabegron on the Body's Exercise Capacity: A Review. Baska, A; Gałązka, P; Leis, K; Mazur, E; Racinowski, M; Świerczyński, W, 2020)	2.4
"Mirabegron is an effective drug to treat male OAB regardless of IPP grade."	( Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder. Chen, CH; Chuang, YC; Lee, WC; Shen, YC; Wang, HJ, 2020)	2.23
"Mirabegron is a safe and effective alternative therapy for females with OAB."	( Mirabegron in female patients with overactive bladder syndrome: What's new? A systematic review and meta-analysis. Athanasiou, S; Grigoriadis, T; Pitsouni, E; Salvatore, S; Serati, M; Zacharakis, D, 2020)	2.72
"Mirabegron was judged to be an effective treatment for 990/1296 (76.4%) patients without BPH, 1935/2491 (77.7%) patients with BPH + treatment, and 421/538 (78.3%) patients with BPH + no treatment."	( Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study. Kato, D; Tabuchi, H; Takahashi, S; Uno, S, 2021)	1.64
"Mirabegron is a well-tolerated add-on therapy to tamsulosin in Japanese and Korean males with residual overactive bladder symptoms."	( Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study. Ishida, K; Jong, JJ; Kakizaki, H; Katoh, T; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O, 2021)	1.65
"Mirabegron is an effective and safe treatment for men with OAB and BPH."	( Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia. Kaplan, SA; Mullen, GR, 2021)	1.65
"Mirabegron is an effective treatment for patients with storage lower urinary tract symptoms/overactive bladder, providing a reduction of incontinence, urgency and frequency; an improvement of voided volume with a slight, but statistically, significant improvement of nocturia; with a good safety profile."	( Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. Chapple, C; Gacci, M; Gravas, S; Kaplan, SA; McVary, KT; Moncada, I; Morgia, G; Russo, GI; Sebastianelli, A; Serni, S, 2018)	1.43
"Mirabegron is a novel medication for the treatment of OAB."	( Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. Chen, SF; Kuo, HC, 2019)	1.5
"Mirabegron is a β"	( Mirabegron, a β Alexandre, EM; Antunes, E; Lescano, CH; Mendes-Silvério, CB; Mónica, FZ, 2018)	3.37
"Mirabegron is an established treatment alternative to antimuscarinic therapy for patients with overactive bladder (OAB), as shown by efficacy and tolerability data from phase III trials."	( Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. Aballéa, S; Chapple, C; Hakimi, Z; Kelleher, C; Maman, K; Nazir, J; Siddiqui, E; Zur, R, 2018)	2.21
"Mirabegron is a relatively new drug to treat overactive bladder (OAB). "	( Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice. Chuang, YC; Shen, YC; Wang, HJ, 2018)	2.2
"Mirabegron is a selective 3-adrenoreceptors agonist, which represent a new approach to the treatment of patients with overactive bladder."	( [New approach to the treatment of patients with overactive bladder. Mirabegron: past, present and future]. Korshunova, ES, 2018)	1.44
"Mirabegron is an effective first-line therapy for OAB, but has a persistence rate of 39.4% at 12 months. "	( Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice. Choo, MS; Shin, JH, 2019)	2.24
"Mirabegron is a kind of β3 adrenergic receptor agonist which is an effective drug for the treatment of overactive bladder. "	( Determination of Mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration. Chen, L; Zhang, Y, 2019)	2.3
"Mirabegron (Myrbetriq) is a β3-adrenoreceptor agonist approved for treating overactive bladder syndrome in human patients. "	( Bladder drug mirabegron exacerbates atherosclerosis through activation of brown fat-mediated lipolysis. Cao, Y; Chen, Y; Cheng, J; Dong, M; Jing, X; Li, H; Pan, H; Shi, W; Sui, W; Wang, X; Xue, F; Yang, Y; Zhang, C; Zhang, H; Zhang, M; Zhang, Y; Zhou, Q, 2019)	2.33
"Mirabegron is a moderate CYP2D6 inhibitor and weak CYP3A inhibitor."	( Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron. Goosen, TC; Lin, J; Malhotra, B; Tse, S; Yamagami, H, 2019)	1.44
"Mirabegron is a potent and selective β3-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder."	( A phase II dose-ranging study of mirabegron in patients with overactive bladder. Boerrigter, P; Bosman, B; Chapple, CR; Drogendijk, T; Dvorak, V; Radziszewski, P; Ridder, A; Van Der Putten-Slob, I; Van Kerrebroeck, P; Wyndaele, JJ; Yamaguchi, O, 2013)	2.11
"Mirabegron is a β3-adrenoceptor agonist used for the treatment of overactive bladder. "	( Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults. Grunenberg, N; Keirns, J; Kerbusch, V; Kowalski, D; Lee, J; Moy, S; Sawamoto, T; van Gelderen, M; Zhang, W, 2013)	2.07
"Mirabegron is a new once-daily, oral treatment for management of overactive bladder (OAB) that is approved in USA, EU and Japan. "	( The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Kashyap, M; Tyagi, P, 2013)	2.11
"Mirabegron is a first-in-class of β3 adrenoceptor agonists that could offer an alternative to antimuscarinics for OAB patients. "	( The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Kashyap, M; Tyagi, P, 2013)	2.11
"Mirabegron is a β3-adrenoceptor agonist for the treatment of overactive bladder. "	( Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. Keirns, J; Kerbusch, V; Kowalski, D; Krauwinkel, W; Lee, J; Marion, A; Meijer, J; Moy, S; Roy, M; Sawamoto, T; Takusagawa, S; van Gelderen, M, 2013)	2.06
"Mirabegron is a potent and selective β3-adrenoceptor agonist developed for the treatment of overactive bladder. "	( The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Dickinson, J; Krauwinkel, W; Meijer, J; Schaddelee, M; Strabach, G; Tretter, R; van de Wetering, J; van Gelderen, M, 2014)	2.21
"Mirabegron is a novel β3-adrenoceptor agonist developed for the treatment of overactive bladder. "	( Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys. Hatanaka, T; Masuda, N; Ohtake, A; Sato, S; Someya, A; Suzuki, M; Ueshima, K; Ukai, M; Watanabe, M, 2013)	2.07
"Mirabegron is an efficacious drug which presents a statistically significant reduction in the number of incontinence episodes and in urinary frequency as of 4 weeks, with a higher percentage of dry patients and a higher percentage of patients with reduction ≥50% in the number of incontinence episodes than placebo. "	( Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder. Angulo, JC; Khullar, V; Nitti, VW; Siddiqui, E, )	1.81
"Mirabegron is a novel β3-adrenoceptor agonist recently approved by Japanese, American, and European authorities for overactive bladder (OAB) therapy. "	( What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder? Caremel, R; Corcos, J; Loutochin, O, 2014)	2.12
"Mirabegron is a β3-adrenoceptor agonist developed for the treatment of OAB, with a mechanism of action distinct from that of antimuscarinics."	( Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. Angulo, JC; Blauwet, MB; Cambronero, J; Dorrepaal, C; Khullar, V; Martin, NE; Wooning, M, 2013)	1.49
"Mirabegron appears to be a promising treatment in OAB patients by shifting its management from reducing detrusor over-activity to inducing relaxation. "	( Mirabegron for overactive bladder: a novel, first-in-class β3-agonist therapy. Imran, M; Najmi, AK; Tabrez, S, 2013)	3.28
"Mirabegron is a human β3-adrenoceptor agonist for the treatment of overactive bladder. "	( Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies. Amada, Y; Iitsuka, H; Katashima, M; Matsushima, H; Miyahara, H; Sawamoto, T; Takusagawa, S; Tanaka, T; Tokuno, T; van Gelderen, M, 2014)	2.17
"Mirabegron is a first-in-class β3-adrenoceptor agonist licensed for the treatment of OAB and has shown to be well tolerated and effective in the treatment of OAB symptoms."	( Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Aballea, S; Desroziers, K; Hakimi, Z; Maman, K; Nazir, J; Neine, ME; Odeyemi, I; Siddiqui, E, 2014)	1.12
"mirabegron is a β3-adrenoceptor agonist developed for the treatment of symptoms of overactive bladder (OAB). "	( The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Auerbach, S; Blauwet, MB; Cardozo, L; Castro-Diaz, D; Nitti, VW; Siddiqui, E; Wagg, A, 2014)	2.09
"Mirabegron is a selective β3-adrenergic receptor agonist recently developed for the treatment of patients with overactive bladder (OAB), which offers an alternative pharmacological option to the well-established treatment with antimuscarinics (AMs)."	( Mirabegron in the treatment of overactive bladder. Candiani, M; Cardozo, L; Cola, A; Colacurci, N; Del Deo, F; Ferrero, S; Leone Roberti Maggiore, U; Salvatore, S; Sileo, F; Torella, M, 2014)	3.29
"Mirabegron is a new beta 3 agonist for the treatment of overactive bladder (OAB). "	( Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy? Balachandran, A; Basu, M; Curtiss, N; Duckett, J, 2015)	2.11
"Mirabegron is a new selective β3-adrenoreceptor agonist licensed for the treatment of overactive bladder (OAB). "	( The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder. Balachandran, AA; Duckett, JR, 2015)	2.09
"Mirabegron is a new treatment option for all patients with OAB and could solve an unmet need in patients still not satisfied, or where the antimuscarinic therapy is not indicated, is an alternative option for patients with OAB."	( [Developments in the medical treatment of overactive bladder]. Alcántara Montero, A, )	0.85
"Mirabegron is a treatment option for patients with overactive bladder. "	( The efficacy and tolerability of mirabegron in a non-trial clinical setting. Balachandran, A; Duckett, J, 2016)	2.16
"Mirabegron has shown to be a drug with the better balance between efficacy and tolerability in women with OAB."	( Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study. Morosetti, C; Vecchioli Scaldazza, C, 2016)	2.1
"Mirabegron is a β3-adrenoreceptor agonist developed for treatment of overactive bladder (OAB). "	( The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men. Asai, A; Kakoki, K; Matsuo, T; Miyata, Y; Ohba, K; Sakai, H; Yuzuriha, M, 2016)	2.22
"Mirabegron is a hydrophilic drug that exhibits pH-dependent solubility."	( Oral Sustained Release of a Hydrophilic Drug Using the Lauryl Sulfate Salt/Complex. Kasashima, Y; Namiki, N; Sako, K; Uchida, S; Yasuji, T; Yoshihara, K, 2016)	1.16
"Mirabegron is a relatively new drug introduced to treat overactive bladder syndrome. "	( Profile of mirabegron in the treatment of overactive bladder: place in therapy. Hashim, H; Sharaf, A, 2017)	2.29
"Mirabegron is a β(3)-adrenoceptor agonist developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile for OAB patients with advanced age and cognitive deficit. "	( Mirabegron: a safety review. Chancellor, M; Tyagi, P; Tyagi, V, 2011)	3.25
"Mirabegron is a promising alternative to antimuscarinics."	( Use of mirabegron in treating overactive bladder. Bhide, AA; Digesu, GA; Fernando, R; Khullar, V, 2012)	1.56
"Mirabegron is a potent and selective β3-adrenoceptor agonist in development for treatment of overactive bladder."	( Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder. Drogendijk, T; Eltink, C; Grunenberg, N; Iitsuka, H; Kerbusch, V; Kowalski, D; Lee, J; Matsushima, H; Meijer, J; Moy, S; Sawamoto, T; Schaddelee, M; van Gelderen, M; van Marle, S; Zhang, W, 2012)	2.06
"Mirabegron (YM178) is a β(3)-adrenoceptor agonist for the treatment of overactive bladder (OAB). "	( Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Eltink, C; Kerbusch, V; Krauwinkel, W; Meijer, J; Schaddelee, M; Strabach, G; van Dijk, J; van Gelderen, M; van Marle, S, 2012)	2.11

Excerpt	Reference	Relevance
"Mirabegron has a similar efficacy profile to first-line antimuscarinics with favorable adverse effects profile. "	( Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder? Campeau, L; Fogaing, C; Mossa, AH, 2020)	2
"Mirabegron has an excellent safety profile and appears to be an effective treatment for overactive bladder symptoms in patients with PD. "	( Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort. Biagioni, MC; Brucker, BM; Feigin, A; Frucht, S; Gilbert, R; Kaufmann, H; Malacarne, DR; Nitti, VW; Palma, JA; Palmerola, R; Peyronnet, B; Rosenblum, N; Sussman, RD; Vurture, G, 2018)	3.37
"Mirabegron has a more favorable tolerability profile than antimuscarinics amongst older patients and may provide an improved benefit-to-risk ratio and therefore be considered as an alternative to antimuscarinics for older patients."	( Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Berner, T; Castro-Diaz, D; Kelleher, C; Nitti, VW; Siddiqui, E; Wagg, A, 2016)	2.12
"Mirabegron has a favorable safety and tolerability profile, particularly compared with antimuscarinics, for dry mouth, constipation, and many CNS effects, which is maintained over 1 year."	( Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia. Chapple, CR; Siddiqui, E, 2017)	2.62
"Mirabegron has been classified as a β"	( The β Kaumann, AJ; Lee, XW; Michel, MC; Mo, W; Molenaar, P, 2017)	1.9
"Mirabegron has shown to be a drug with the better balance between efficacy and tolerability in women with OAB."	( Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study. Morosetti, C; Vecchioli Scaldazza, C, 2016)	2.1
"Mirabegron has been approved in Japan for the indication of urgency, urinary frequency and urge urinary incontinence associated with OAB, and was recently submitted for approval to U.S."	( Mirabegron for the treatment of overactive bladder. Gras, J, 2012)	2.54

Excerpt	Reference	Relevance
"Mirabegron's ability to increase adiponectin in serum and decrease glutathione, GSTM1, and catalase in the colon may account for its protective effects."	( Mirabegron alleviates acetic acid-induced colitis in rats: Role of adiponectin and GSTM1/GSH detoxification pathway. Abed El Baky, MF; Hafez, HM; Mohamed, MZ; Mokhemer, SA, 2023)	3.07
"Mirabegron also had a lower adverse reaction rate (OR 0.9; 95% CI 0.8, 1.0; p = 0.04)."	( The role of mirabegron in overactive bladder: a systematic review and meta-analysis. Bu, SY; Cao, CX; Duan, X; Peng, CD; Wang, KJ; Wu, T, 2014)	1.5
"Mirabegron may also cause a dose-dependent increase in blood pressure."	( mirabegron (BETMIGA⁰). Poorly effective in urge urinary incontinence. , 2016)	2.6
"Mirabegron didn't produce significant inhibitory effects in any of the contractile elements in either species."	( The actions of isoprenaline and mirabegron in the isolated whole rat and guinea pig bladder. De Wachter, S; Eastham, J; Gillespie, J; Persyn, S; Wyndaele, JJ, 2016)	1.44

Excerpt	Reference	Relevance
"Mirabegron is used for treatment of storage symptoms in overactive bladder (OAB) caused by spontaneous bladder smooth muscle contractions. "	( Inhibition of Full Smooth Muscle Contraction in Isolated Human Detrusor Tissues by Mirabegron Is Limited to Off-Target Inhibition of Neurogenic Contractions. Hennenberg, M; Huang, R; Stief, CG; Strittmatter, F; Tamalunas, A; Waidelich, R, 2022)	2.39
"Mirabegron treatment significantly improved BOO-induced bladder dysfunction through the amelioration of bladder blood flow."	( The effect of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction. Funahashi, Y; Gotoh, M; Kato, M; Majima, T; Matsukawa, Y; Yamamoto, T, 2020)	2.36
"Mirabegron treatment was well-tolerated in older adults with OAB-wet. "	( Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet. Herschorn, S; Kristy, RM; Schermer, CR; Staskin, D; Wagg, A, 2020)	2.21
"Mirabegron as adjuvant treatment in children with refractory neurogenic bladder increased bladder capacity, reduced intravesical pressure and helped achieve continence in more than two thirds of the sample population. "	( Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction. Burek, C; Corbetta, JP; Gomez, YR; Lopez Imizcoz, F; Ruiz, J; Sager, C; Sanmartino, M; Szklarz, T; Tessi, C; Vazquez Patiño, M; Weller, S, 2020)	2.31
"Mirabegron treatment improved the IIEF-5 scores in five patients (38.4%) by 4 points or more, whereas IIEF-5 scores were not affected by Mirabegron treatment in eight patients (61.5%)."	( Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction: a 12-week pilot study. Burnett, AL; Karakus, S; Musicki, B, 2022)	2.89
"Most mirabegron treatment failures were because of treatment discontinuation (67%) versus switching to ACH therapy (14%)."	( Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Chaudhari, S; Kish, J; Kowalski, J; Lee, W; Murray, B; Sussman, D; Yehoshua, A, 2017)	1.2
"Mirabegron treatment persistence was higher than has been previously reported, and was greater in patients aged ≥65 years compared with those aged <65 years."	( Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study. Kato, D; Tabuchi, H; Uno, S, 2019)	1.49
"Mirabegron treatment was associated with longer median persistence compared with antimuscarinics (insurance claims: 44 [95% confidence intervals 37-56] vs 21 [14-28] to 30 [30-33] days, pharmacy claims: 105 [96-113] vs 62 [56-77] to 84 [77-86] days)."	( Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis. Fan, A; Kato, D; Kimura, T; Uno, S; Van Schyndle, J, 2017)	1.18
"Mirabegron treatment improved OABSS in terms of night-time frequency, urgency, and total score (P < .001). "	( Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy. Matsuo, T; Miyata, Y; Nakamura, T; Sakai, H; Satoh, K, 2019)	2.34
"Mirabegron treatment significantly increased first desire to void and cystometric capacity with an average increment of 80 mL (P = 0.027) and 123 mL (P = 0.005), respectively. "	( Video-urodynamic effects of mirabegron, a β3 -adrenoceptor agonist, in patients with low-compliance bladder. Akiyama, Y; Fujimura, T; Fukuhara, H; Furuta, A; Homma, Y; Ichihara, K; Igawa, Y; Kamei, J; Kume, H; Niimi, A, 2015)	2.15
"Mirabegron is a new treatment option for all patients with OAB and could solve an unmet need in patients still not satisfied, or where the antimuscarinic therapy is not indicated, is an alternative option for patients with OAB."	( [Developments in the medical treatment of overactive bladder]. Alcántara Montero, A, )	0.85
"Mirabegron is a treatment option for patients with overactive bladder. "	( The efficacy and tolerability of mirabegron in a non-trial clinical setting. Balachandran, A; Duckett, J, 2016)	2.16
"Mirabegron treatment is associated with a satisfactory cardiovascular safety profile, as well as, significant symptomatic improvement also in a heterogeneous population of non-selected women with overactive bladder presenting in everyday clinical practice."	( Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study. Altman, D; Christensson, AA; Elmér, C; Flam, B; Kallner, HK, 2016)	2.19
"Mirabegron add-on treatment with tamsulosin has efficacy and safety because it improves storage symptom without impairment of bladder contractility during voiding in male patients with OAB."	( Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder. Hashizume, K; Iuchi, H; Kakizaki, H; Kita, M; Matsumoto, S; Wada, N, 2016)	2.16
"Mice treated with mirabegron or solifenacin displayed significantly fewer voiding events compared to the stressed mice, and voiding frequency in drug-treated animals was comparable to unstressed controls."	( Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice. Chess-Williams, R; McDermott, C; Sellers, DJ; West, EG, 2022)	2.49
"Treatment with mirabegron resulted in significant changes in symptoms and urodynamic sensory markers in patients with URI."	( Exploratory analysis of the effect of mirabegron on urodynamic sensation parameters and urethral pressure variations. Egberts, J; Elzevier, HW; Groenendijk, PM; Kummeling, MTM; Putter, H; van Koeveringe, GA, 2021)	1.23
"Treatment with mirabegron for 12 weeks did not contribute to drug-related cognitive side effects in patients aged ≥65 years, as measured by the MoCA. "	( Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). Campbell, NL; Elsouda, D; Griebling, TL; Herschorn, S; Mangel, J; Schermer, CR; Staskin, D, 2020)	1.31
"Treatment with mirabegron could generate savings of 80.74 ±4.61 € per patient per year compared to AM, assuming 100% probability of saving."	( [Analysis of costs and consequences related to the persistence of Mirabegron and antimuscarinic treatments and their impact on quality of life in patients with overactive bladder in Spain: Results of a probabilistic model.] Arlandis Guzmán, S; Blanco, N; Jiménez Cidre, MÁ; Landeira, M; Rubio-Rodríguez, D; Rubio-Terrés, C, 2020)	1.13
"Treatment with mirabegron and desmopressin revealed both effectiveness and safety in patients with NDO and MS."	( Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Baltogiannis, D; Dimitriadis, F; Filiponi, M; Giannakis, J; Sofikitis, N; Takenaka, A; Tsounapi, P; Zachariou, A, 2017)	1.02
"Treatment with mirabegron reduced the percentage of patients suffering from frequency after 6 weeks."	( Does Pharmacological Treatment Reduce the Incidence of Lower Urinary Tract Symptoms (LUTS) after Transobturator Sling? Bogusiewicz, M; Kulik-Rechberger, B; Miotla, P; Rechberger, E; Rechberger, T; Wrobel, A; Zietek, A, 2019)	0.85
"Treatment with mirabegron 50 and 100 mg was noninferior to placebo based on the lower and upper limits of the 95% CI, respectively, for maximum urinary flow and detrusor pressure at maximum urinary flow. "	( Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. Fakhoury, A; He, W; Martin, NE; Mitcheson, DH; Nitti, VW; Rosenberg, S, 2013)	0.99

Excerpt	Reference	Relevance
" However, long-term adverse effects are not yet completely investigated."	( Mirabegron: a safety review. Chancellor, M; Tyagi, P; Tyagi, V, 2011)	1.81
" The most commonly reported toxic effects of mirabegron are gastrointestinal adverse events and headache."	( Mirabegron: a safety review. Chancellor, M; Tyagi, P; Tyagi, V, 2011)	2.07
" No treatment-emergent adverse event (AE) of glaucoma was reported."	( Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers. Hantsbarger, G; Lewis, RA; Martin, NE; Novack, GD; Rasmussen, S; Sheth, N; Swearingen, D; Vogel, R, 2013)	0.61
"Mirabegron 100 mg orally once daily for 8 weeks of treatment does not increase the IOP, and was generally safe and well tolerated."	( Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers. Hantsbarger, G; Lewis, RA; Martin, NE; Novack, GD; Rasmussen, S; Sheth, N; Swearingen, D; Vogel, R, 2013)	2.06
" The safety analysis included adverse event (AE) reporting, laboratory assessments, ECG, postvoid residual volume and vital signs (blood pressure, pulse rate)."	( Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Angulo, JC; Blauwet, MB; Cambronero, J; Dorrepaal, C; Herschorn, S; Khullar, V; Martin, NE; Nitti, VW; Siddiqui, E; van Kerrebroeck, P, 2013)	1.83
" We evaluated adverse events and vital signs."	( Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. Fakhoury, A; He, W; Martin, NE; Mitcheson, DH; Nitti, VW; Rosenberg, S, 2013)	0.64
" The incidence of adverse events was similar for mirabegron and placebo."	( Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. Fakhoury, A; He, W; Martin, NE; Mitcheson, DH; Nitti, VW; Rosenberg, S, 2013)	0.89
" Statistically significant improvements vs placebo were demonstrated by mirabegron 50 mg in all patient-reported outcome scales with no increase in the incidence of treatment-emergent adverse events vs placebo."	( A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Barkin, J; Castro-Diaz, D; Espuna-Pons, M; Frankel, JM; Gousse, AE; Gunther, A; Herschorn, S; Martin, N; Stölzel, M; Van Kerrebroeck, P, 2013)	0.82
"This meta-analysis indicates that mirabegron to be an effective and safe treatment for OAB symptoms with a low occurrence of side effects."	( The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Cui, Y; Yan, H; Yang, C; Zhang, Y; Zong, H, 2014)	0.98
" The most common adverse events (AEs) observed with mirabegron in clinical trials of up to 12 months were hypertension, nasopharyngitis, and urinary tract infection."	( Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Cardozo, L; Chapple, CR; Michel, MC; Nitti, VW; Siddiqui, E, 2014)	2.1
" This review included randomised controlled trials (RCTs) studying changes in symptoms (micturition frequency, incontinence, and urgency urinary incontinence [UUI] episodes) and incidence of the most frequently reported adverse events (dry mouth, constipation) associated with current OAB medications."	( Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Aballea, S; Desroziers, K; Hakimi, Z; Maman, K; Nazir, J; Neine, ME; Odeyemi, I; Siddiqui, E, 2014)	0.4
"Mirabegron 50 mg had similar efficacy to most antimuscarinics and lower incidence of dry mouth, the most common adverse event reported with antimuscarinics and one of the main causes of discontinuation of treatment."	( Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Aballea, S; Desroziers, K; Hakimi, Z; Maman, K; Nazir, J; Neine, ME; Odeyemi, I; Siddiqui, E, 2014)	1.85
" Safety assessments included treatment-emergent adverse events (TEAEs), blood pressure, pulse rate, postvoid residual (PVR) volume, and laboratory and electrocardiography (ECG) parameters."	( Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Abrams, P; Kay, R; Kelleher, C; Martina, R; Newgreen, D; Paireddy, A; Rechberger, T; Ridder, A; Staskin, D; van Maanen, R, 2015)	0.71
" Safety variables included the incidence and severity of treatment-emergent adverse events (TEAEs), vital signs and electrocardiogram data."	( Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. Auerbach, S; Blauwet, MB; Chapple, CR; Herschorn, S; Milsom, I; Nitti, VW; Radziszewski, P; Walters, C, 2014)	0.65
"Mirabegron (25, 50 or 100 mg qd) was safe and well-tolerated in patients with OAB over 12-week (n = 2736) and 1-year (n = 1632) periods."	( Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. Auerbach, S; Blauwet, MB; Chapple, CR; Herschorn, S; Milsom, I; Nitti, VW; Radziszewski, P; Walters, C, 2014)	2.09
" Safety assessments included adverse events (AEs), laboratory tests, vital signs, 12-lead electrocardiogram, QT corrected for heart rate using Fridericia's correction (QTcF) interval and post-void residual (PVR) volume."	( Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M, 2015)	0.73
" Safety was evaluated based on adverse events (AEs), laboratory findings, vital signs, electrocardiogram, and post-void residual volume."	( Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study. Igawa, Y; Ikeda, Y; Marui, E; Nishizawa, O; Ohkawa, S; Takeda, M; Yamaguchi, O, 2015)	0.66
"Based on a systematic PubMed search, incidence of overall adverse events, hypertension, dry mouth, and constipation are comparable between mirabegron or solabegron and placebo."	( Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies. Gravas, S; Michel, MC, 2016)	0.64
" We propose that expression profiles and functional preclinical studies can be important tools in the prediction of adverse event profiles in first-in-class drugs."	( Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies. Gravas, S; Michel, MC, 2016)	0.43
" Antimuscarinics are currently the most widely prescribed drugs for OAB although persistence with medication is often limited due to lack of efficacy or intolerable adverse effects."	( A drug safety evaluation of mirabegron in the management of overactive bladder. Cardozo, L; Robinson, D; Thiagamoorthy, G, 2016)	0.73
"The extensive clinical trial programme has shown mirabegron to be safe and efficacious in the treatment of OAB symptoms and the evidence would suggest that it offers an effective alternative to antimuscarinic therapy."	( A drug safety evaluation of mirabegron in the management of overactive bladder. Cardozo, L; Robinson, D; Thiagamoorthy, G, 2016)	0.98
" Data on adverse events, cardiovascular outcomes, condition specific symptoms and drug discontinuation was collected at two months follow-up (FU)."	( Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study. Altman, D; Christensson, AA; Elmér, C; Flam, B; Kallner, HK, 2016)	0.74
" Safety assessments included adverse events, vital signs, post-void residual volume and patient-reported incidence, and severity of distinctive symptoms related to adverse events."	( Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study). Furuse, H; Kageyama, S; Kitagawa, M; Matsumoto, R; Nagae, H; Otsuka, A; Ozono, S; Suzuki, T, 2016)	0.79
" The overall incidence of adverse events and the incidence of dry mouth were significantly higher in the imidafenacin group than in the mirabegron group."	( Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study). Furuse, H; Kageyama, S; Kitagawa, M; Matsumoto, R; Nagae, H; Otsuka, A; Ozono, S; Suzuki, T, 2016)	1
"Treatment with 50 mg mirabegron once daily effectively relieves overactive bladder symptoms in women with fewer adverse events than treatment with antimuscarinics."	( Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study). Furuse, H; Kageyama, S; Kitagawa, M; Matsumoto, R; Nagae, H; Otsuka, A; Ozono, S; Suzuki, T, 2016)	1.11
" Safety was evaluated based on vital signs, adverse events (AEs), laboratory findings, electrocardiogram and post-void residual volume."	( Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β Ikeda, Y; Ohkawa, S; Yamaguchi, O, 2017)	0.69
"Study the efficacy and adverse events of different pharmacological lines in the treatment of idiopathic overactive bladder (iOAB)."	( [Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature]. Legrand, F; Moyson, J; Quackels, T; Roumeguère, T; Vanden Bossche, M, 2017)	0.46
"PubMed research on meta-analyses and randomized controlled trials (RCT) focused on the efficacy and adverse effects of anticholinergics, botulinum toxin and mirabegron since 2005."	( [Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature]. Legrand, F; Moyson, J; Quackels, T; Roumeguère, T; Vanden Bossche, M, 2017)	0.65
" The most commonly reported side effect is dry mouth (30 % vs."	( [Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature]. Legrand, F; Moyson, J; Quackels, T; Roumeguère, T; Vanden Bossche, M, 2017)	0.46
" Safety assessments included incidence and frequency of treatment-emergent adverse events (TEAEs), post-void residual (PVR) urine volume, and changes from baseline in laboratory parameters."	( Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). Abrams, P; Arlandis, S; Chapple, CR; Herschorn, S; Lee, KS; Mitcheson, D; Paireddy, A; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R, 2017)	0.72
" CV safety assessments included frequency of CV-related treatment-emergent adverse events (TEAEs), change from baseline in vital signs (systolic blood pressure [SBP], diastolic blood pressure [DBP], pulse rate) and electrocardiogram (ECG) parameters."	( Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). Athanasiou, S; Cambronero Santos, J; Chapple, CR; Drake, MJ; Esen, A; Herschorn, S; Huang, M; MacDiarmid, S; Mitcheson, D; Siddiqui, E; Stoelzel, M, 2017)	0.67
" Data were collected on adverse drug reactions (ADR), changes in OAB symptoms, changes in Overactive Bladder Symptom Score (OABSS), and treatment discontinuations."	( Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study. Kato, D; Tabuchi, H; Uno, S, 2019)	0.77
" Despite evidence showing that the use of vaginal oestrogens is safe in those with a history of cancer, it is not fully supported by any health body."	( Safety issues associated with using medication to treat overactive bladder. Araklitis, G; Cardozo, L, 2017)	0.46
"Incidence of adverse drug reactions (ADR) was assessed following 12 weeks' mirabegron treatment."	( Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study. Kato, D; Kuroishi, K; Nozawa, Y; Tabuchi, H; Yoshida, M, 2019)	1.04
" Safety assessments included monitoring the incidence and severity of adverse events."	( Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study. Bílková, K; Borovička, V; Krhut, J; Míka, D; Mokriš, J; Sýkora, R; Zachoval, R, 2018)	0.79
" Although most adverse events (AEs) were mild, patients with BOO had significantly higher AEs rate (18."	( Mirabegron 25 mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction. Kuo, HC; Liao, CH, 2018)	1.92
" Subjective symptom scores, uroflowmetry data, and adverse events (AEs) were recorded for all patients at baseline and after 1, 3, and 6 months treatment."	( Efficacy and safety of mirabegron, a β Kuo, HC; Lee, CL, 2019)	0.82
"The primary objective was safety, measured as treatment-emergent adverse events (TEAEs)."	( Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Abrams, P; Al-Shukri, S; Chapple, C; Gratzke, C; Herschorn, S; Mueller, ER; Paireddy, A; Rechberger, T; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R; Yoon, SJ, 2018)	0.76
" Safety assessments included adverse events and post-void residual urine volume."	( Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. Kuo, HC; Lee, YK, 2018)	0.76
" The younger patients experienced more minor adverse events than the older patients (41."	( Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. Kuo, HC; Lee, YK, 2018)	0.76
"Mirabegron 25 mg once daily is a safe and effective treatment for older patients with overactive bladder."	( Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. Kuo, HC; Lee, YK, 2018)	2.2
" Adverse drug reactions (ADRs), residual urine volume measurements, OAB symptoms, Overactive Bladder Symptom Scores (OABSS), and treatment discontinuations were evaluated prospectively."	( Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study. Kato, D; Tabuchi, H; Uno, S, 2019)	0.74
" Safety assessments included treatment-emergent adverse events, blood pressure, pulse rate, postvoid residual volume, and maximum urinary flow rate."	( Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study. Bae, JH; Jeong, SJ; Joo, KJ; Kang, TW; Kim, HW; Kim, SW; Kim, YH; Koo, KC; Lee, YG; Shin, DG; Son, H; Song, SH; Woo, SH; Yoo, ES; Yoon, SJ, 2019)	1.96
"A daily 50 mg dose of mirabegron for 12 weeks reduced OAB symptoms in men, and no significant adverse events compared to the placebo group were noted."	( Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study. Bae, JH; Jeong, SJ; Joo, KJ; Kang, TW; Kim, HW; Kim, SW; Kim, YH; Koo, KC; Lee, YG; Shin, DG; Son, H; Song, SH; Woo, SH; Yoo, ES; Yoon, SJ, 2019)	2.27
" With regard to drug-related treatment-emergent adverse events (DR-TEAEs) and dry mouth, mirabegron showed better tolerance than solifenacin."	( Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Cui, Y; Gao, Z; Li, Y; Wang, J; Wu, J; Yuan, H; Zhou, Z; Zhu, Z, 2019)	1
"The therapeutic effect of mirabegron is similar to that of solifenacin, and mirabegron does not increase the risk of adverse events (AEs)."	( Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Cui, Y; Gao, Z; Li, Y; Wang, J; Wu, J; Yuan, H; Zhou, Z; Zhu, Z, 2019)	1.08
" Urodynamic parameters, including compliance, involuntary detrusor contraction, and maximum cystometric capacity, as well as patient-reported efficacy and adverse events, were measured."	( Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. Han, SW; Kim, SH; Kim, SW; Lee, CN; Lee, YS; Park, JS, 2019)	0.82
" Safety assessments included treatment-emergent adverse events, vital signs, 12-lead electrocardiograms, post-void residual volume, and laboratory evaluations."	( Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study). Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M, 2019)	0.72
"1% women, mean age 65 years) experienced at least one treatment-emergent adverse event, with similar rates for all treatments."	( Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study). Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M, 2019)	0.72
" The OAB symptom score (OABSS), Vaginal Health Index Scale (VHIS), and occurrence of adverse effects were examined prior to and at 1 year following treatment initiation."	( Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists. Okui, N, 2019)	0.51
" Regarding safety, no adverse events were observed in the VEL group."	( Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists. Okui, N, 2019)	0.51
" CV safety was assessed using treatment-emergent adverse events (TEAEs), vital signs, and 12-lead electrocardiograms (ECGs)."	( Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study. Hamada, T; Igawa, Y; Kato, D; Katoh, T; Kuroishi, K; Yamaguchi, O, 2020)	0.76
" Safety was evaluated using the proportion of treatment-emergent adverse events."	( Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. Cardozo, L; Chapple, CR; Choudhury, N; Cruz, F; Heesakkers, J; Herschorn, S; Siddiqui, E; Staskin, D; Stoelzel, M, 2020)	0.87
" Safety assessments included treatment emergent adverse events, and post-void residual volume, and maximum urinary flow measurements."	( Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). Cambronero Santos, J; Chapple, C; Choudhury, N; Foley, S; Hairston, J; Herschorn, S; Kaplan, SA; Kristy, RM; McVary, KT; Schermer, CR; Staskin, D, 2020)	0.87
" Higher overall treatment emergent adverse event rates were observed with tamsulosin plus placebo, although higher rates of drug related treatment emergent adverse events were noted with tamsulosin plus mirabegron."	( Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). Cambronero Santos, J; Chapple, C; Choudhury, N; Foley, S; Hairston, J; Herschorn, S; Kaplan, SA; Kristy, RM; McVary, KT; Schermer, CR; Staskin, D, 2020)	1.06
" Safety assessments that included treatment-emergent adverse events (odds ratio = 0."	( The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis. Chen, Z; Gao, Y; Liang, L; Lin, J; Liu, L; Su, S, 2020)	0.86
"This analysis demonstrates that mirabegron is an effective and safe treatment for OAB symptoms induced by BPH in men receiving tamsulosin therapy with a low occurrence of side effects."	( The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis. Chen, Z; Gao, Y; Liang, L; Lin, J; Liu, L; Su, S, 2020)	1.14
" Safety analyses were performed for adverse events (AEs) and vital signs on all randomized patients who received one or more dose of study drug."	( Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet. Herschorn, S; Kristy, RM; Schermer, CR; Staskin, D; Wagg, A, 2020)	0.77
" Assessments included adverse drug reactions (ADRs), residual urine volume evaluations, and total Overactive Bladder Symptom Score (OABSS) and International Prostate Symptom Score-Quality of Life (IPSS-QoL) measurements."	( Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study. Kato, D; Tabuchi, H; Takahashi, S; Uno, S, 2021)	0.92
" We did not observe any adverse effects."	( Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction. Burek, C; Corbetta, JP; Gomez, YR; Lopez Imizcoz, F; Ruiz, J; Sager, C; Sanmartino, M; Szklarz, T; Tessi, C; Vazquez Patiño, M; Weller, S, 2020)	0.87
" Mirabegron was safe and well tolerated by children."	( Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction. Burek, C; Corbetta, JP; Gomez, YR; Lopez Imizcoz, F; Ruiz, J; Sager, C; Sanmartino, M; Szklarz, T; Tessi, C; Vazquez Patiño, M; Weller, S, 2020)	1.78
"Cumulative exposure to one or more anticholinergic medications ("anticholinergic burden") is associated with an increased risk of adverse outcomes, particularly among older individuals."	( Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis. Hairston, JC; Harrigan, S; Johnston, K; Kristy, RM; Lozano-Ortega, G; Mickle, A; Rogula, B; Schermer, CR; Walker, DR, 2020)	0.56
" In this older population, mirabegron was associated with a similar odds of experiencing adverse event-related treatment discontinuations relative to placebo (0."	( Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis. Hairston, JC; Harrigan, S; Johnston, K; Kristy, RM; Lozano-Ortega, G; Mickle, A; Rogula, B; Schermer, CR; Walker, DR, 2020)	0.86
" The analysis focused on treatment-emergent adverse events relating to the cardiovascular system or blood pressure, and changes in vital signs during 12 weeks of follow-up."	( Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study. Ishida, K; Jong, JJ; Kakizaki, H; Katoh, T; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O, 2021)	0.92
"Cardiovascular-related treatment-emergent adverse events were reported by 6/566 patients, although only one serious treatment-emergent adverse event was related to treatment (unstable angina in the tamsulosin + placebo group)."	( Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study. Ishida, K; Jong, JJ; Kakizaki, H; Katoh, T; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O, 2021)	0.92
"Cardiovascular-related adverse events were uncommon in both treatment groups."	( Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study. Ishida, K; Jong, JJ; Kakizaki, H; Katoh, T; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O, 2021)	0.92
"Mirabegron is efficacious and safe in patients with NDO consequent to traumatic SCI."	( Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity resulting from traumatic spinal cord injury: A prospective study. Kumar, N; Prasad, V; Prashanth, YM; Saurav, K; Tyagi, V; Vasudeva, P; Yadav, S, 2021)	2.37
"Numerous studies have shown mirabegron to be efficacious and safe in treating symptoms of OAB."	( Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia. Kaplan, SA; Mullen, GR, 2021)	1.23
" A single cardiovascular study drug-related adverse event was recorded in a patient with cervical SCI (3."	( Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity. Bílková, K; Borovička, V; Cífková, R; Krhut, J; Kufová, E; Mokriš, J; Pudich, J; Sýkora, R; Wohlfahrt, P; Zachoval, R; Zvara, P, 2021)	0.92
" Efficacy was evaluated using the OABS Score (OABSS), mean change in nocturnal frequency (NF), PVR and IPSS, while safety was assessed by recording treatment emergent adverse events (TEAE)."	( Efficacy and safety of tamsulosin vs its combination with mirabegron in the management of lower urinary tract non-neurogenic overactive bladder symptoms (OABS) because of Benign Prostatic Enlargement (BPE)-An open label randomised controlled clinical stud Behera, DP; Gupta, S; Singh, I; T K, A, 2021)	0.87
"Mirabegron can be significantly efficacious and safe in ameliorating non-neurogenic OABS induced by BPE vs placebo by initiating combination therapy from the start as opposed to the usual 'add on therapy' protocol."	( Efficacy and safety of tamsulosin vs its combination with mirabegron in the management of lower urinary tract non-neurogenic overactive bladder symptoms (OABS) because of Benign Prostatic Enlargement (BPE)-An open label randomised controlled clinical stud Behera, DP; Gupta, S; Singh, I; T K, A, 2021)	2.31
" Randomized controlled trials evaluating safety of mirabegron in overactive bladder were collected, and safety was assessed according to 15 adverse events."	( Adverse events associated with mirabegron 50mg versus placebo: A systematic review and meta-analysis. Du, H; Hou, J; Li, N; Xu, F, 2021)	1.16
"Mirabegron 50mg is further confirmed to be nearly as safe as placebo, expect for nasopharyngitis."	( Adverse events associated with mirabegron 50mg versus placebo: A systematic review and meta-analysis. Du, H; Hou, J; Li, N; Xu, F, 2021)	2.35
" Safety assessments including adverse events (P = ."	( The efficacy and safety of mirabegron in treating ureteral stent-related symptoms: A systematic review and meta-analysis. Chai, Y; Cui, Y; Li, Z; Zhang, Y, 2022)	1.02
"The present meta-analysis shows that mirabegron is an effective and safe treatment for relieving ureteral stent-related symptoms with a low occurrence of adverse events."	( The efficacy and safety of mirabegron in treating ureteral stent-related symptoms: A systematic review and meta-analysis. Chai, Y; Cui, Y; Li, Z; Zhang, Y, 2022)	1.29
" Eligible patients received either darifenacin or mirabegron for a period of 3 months and various parameters on the 3-day International Consultation on Incontinence Questionnaire (ICIQ) bladder diary, the Montreal Cognitive Assessment-Basic score (MoCA-B), and the adverse events at 3 months posttreatment were compared to that at the baseline."	( Neurological safety and efficacy of darifenacin and mirabegron for the treatment of overactive bladder in patients with history of cerebrovascular accident: A prospective study. Chaudhry, N; Kumar, A; Kumar, N; Nagendra Rao, S; Patel, S; Prasad, V; Vasudeva, P; Yadav, P; Yadav, S, 2021)	1.13
" Both are safe and effective treatment options in patients with OAB post-CVA."	( Neurological safety and efficacy of darifenacin and mirabegron for the treatment of overactive bladder in patients with history of cerebrovascular accident: A prospective study. Chaudhry, N; Kumar, A; Kumar, N; Nagendra Rao, S; Patel, S; Prasad, V; Vasudeva, P; Yadav, P; Yadav, S, 2021)	0.87
" Safety assessments included adverse events, electrocardiogram, QT corrected for heart rate using Fridericia's correction (QTcF) interval and blood pressure and pulse rate measurements."	( The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial. Chakra, MA; Dabboucy, B; Dellis, A; Fares, Y; Moussa, M; Papatsoris, A, 2022)	1
" Adverse events were mild and the same in the two groups."	( The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial. Chakra, MA; Dabboucy, B; Dellis, A; Fares, Y; Moussa, M; Papatsoris, A, 2022)	1
" Clinical and urodynamic parameters were pooled to evaluate the efficacy, and safety was measured by adverse events rate."	( The efficacy and safety of mirabegron for adult and child patients with neurogenic lower urinary tract dysfunction: A systematic review and meta-analysis. Boya, L; Chi, Z; Deyi, L; Liao, P; Yuanzhuo, C, 2022)	1.02
"01), showed conspicuous improvements in adult and child patients' urodynamic parameters, while the incidence of adverse events (10."	( The efficacy and safety of mirabegron for adult and child patients with neurogenic lower urinary tract dysfunction: A systematic review and meta-analysis. Boya, L; Chi, Z; Deyi, L; Liao, P; Yuanzhuo, C, 2022)	1.02
"This cohort study evaluates therapeutic efficacy and adverse events (AEs) of various overactive bladder (OAB) medications for patients with central nervous system (CNS) disorders."	( Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders-A cohort study. Chen, SF; Chuang, YC; Kuo, HC; Liao, CH; Wang, CC, 2022)	0.72
" Aim of our study was to analyze real-life data of adverse events related to AMs and B3A reported on Eudra-Vigilance (EV) Database."	( Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database. Cicione, A; DE Nunzio, C; DI Giacomo, F; Disabato, G; Franco, A; Gallo, G; Gravina, C; Lombardo, R; Nacchia, A; Rovesti, L; Trucchi, A; Tubaro, A; Turchi, B, 2022)	0.72
"EV database is the system for managing and analyzing information on suspected adverse reactions to medicines which have been authorized or being studied in clinical trials in the European Economic Area (EEA)."	( Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database. Cicione, A; DE Nunzio, C; DI Giacomo, F; Disabato, G; Franco, A; Gallo, G; Gravina, C; Lombardo, R; Nacchia, A; Rovesti, L; Trucchi, A; Tubaro, A; Turchi, B, 2022)	0.72
" The incidence of drug-related adverse events in the solifenacin group was higher than that in the combination group, but there was no statistically significant difference (P > 0."	( Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study. Liu, YQ; Tang, QL; Tao, RZ; Wu, J; Zhou, S, 2022)	0.99
" Safety outcomes for vibegron and mirabegron were similar to those in the placebo group, except for mirabegron, which had a higher risk of nasopharyngitis and cardiovascular adverse events than placebo."	( Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis. He, W; Huang, G; Liu, X; Sun, Q; Tian, Y; Zhang, Y, 2023)	1.45
"Medication was effective for OAB symptoms in patients with PD, and patients tolerated adverse events well."	( The efficacy and safety of medication for treating overactive bladder in patients with Parkinson's disease: a meta-analysis and systematic review of randomized double-blind placebo-controlled trials. Bao, Y; Cheng, B; Huang, Q; Huang, S; Zhou, Z, 2023)	0.91
" The main secondary outcome was a composite measure of acute care encounters for anticholinergic related adverse events (AEs)."	( Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease. Abraham, DS; Gray, SL; Hennessy, S; Leonard, CE; Liu, Q; Newcomb, CW; Pham Nguyen, TP; Weintraub, D; Willis, AW, 2023)	1.17

Excerpt	Reference	Relevance
" To support the development of mirabegron, including pharmacokinetic studies, liquid chromatography/tandem mass spectrometry methods for mirabegron and eight metabolites (M5, M8, M11-M16) were developed and validated for heparinized human plasma containing sodium fluoride."	( Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study. Beld, Cv; Gelderen, Mv; Meijer, J; Takusagawa, S; Teijlingen, Rv; Usui, T, 2012)	0.9
" Mean half-life was around 40 h for both routes of administration."	( Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder. Drogendijk, T; Eltink, C; Grunenberg, N; Iitsuka, H; Kerbusch, V; Kowalski, D; Lee, J; Matsushima, H; Meijer, J; Moy, S; Sawamoto, T; Schaddelee, M; van Gelderen, M; van Marle, S; Zhang, W, 2012)	0.62
" As part of the clinical development program for mirabegron, 2 human volunteer studies were performed to derive detailed data on the multiple-dose pharmacokinetic (PK) properties of mirabegron."	( Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Eltink, C; Kerbusch, V; Krauwinkel, W; Meijer, J; Schaddelee, M; Strabach, G; van Dijk, J; van Gelderen, M; van Marle, S, 2012)	0.92
" Non-compartmental pharmacokinetic parameters were determined from plasma and urine concentration-time data of mirabegron and metabolites."	( Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Dickinson, J; Keirns, J; Kerbusch, V; Kowalski, D; Krauwinkel, W; Kupčová, V; Lasseter, K; Lewand, M; Meijer, J; Morton, R; Moy, S; Riff, D; Sawamoto, T; Schaddelee, M; van Gelderen, M, 2013)	0.84
" No clear relationship was evident between pharmacokinetic parameters and Child-Pugh scores."	( Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Dickinson, J; Keirns, J; Kerbusch, V; Kowalski, D; Krauwinkel, W; Kupčová, V; Lasseter, K; Lewand, M; Meijer, J; Morton, R; Moy, S; Riff, D; Sawamoto, T; Schaddelee, M; van Gelderen, M, 2013)	0.63
" Pharmacokinetic changes observed in subjects with mild or moderate renal impairment or mild hepatic impairment are of small magnitude and likely to be without clinical importance."	( Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Dickinson, J; Keirns, J; Kerbusch, V; Kowalski, D; Krauwinkel, W; Kupčová, V; Lasseter, K; Lewand, M; Meijer, J; Morton, R; Moy, S; Riff, D; Sawamoto, T; Schaddelee, M; van Gelderen, M, 2013)	0.63
"This study was designed to assess the effects of food on the pharmacokinetic properties of mirabegron OCAS in accordance with regulatory requirements to support dosing recommendations."	( Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults. Grunenberg, N; Keirns, J; Kerbusch, V; Kowalski, D; Lee, J; Moy, S; Sawamoto, T; van Gelderen, M; Zhang, W, 2013)	0.85
" Primary end points for the assessment of food effects were Cmax and AUC0-∞."	( Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults. Grunenberg, N; Keirns, J; Kerbusch, V; Kowalski, D; Lee, J; Moy, S; Sawamoto, T; van Gelderen, M; Zhang, W, 2013)	0.63
" With either fed condition or dose, the 90% CIs for the fed/fasted ratios of both Cmax and AUC0-∞ of mirabegron fell below the predetermined range for bioequivalence (80."	( Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults. Grunenberg, N; Keirns, J; Kerbusch, V; Kowalski, D; Lee, J; Moy, S; Sawamoto, T; van Gelderen, M; Zhang, W, 2013)	0.85
" The pharmacokinetic profile of mirabegron has been extensively characterized in healthy Caucasian subjects."	( Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies. Amada, Y; Iitsuka, H; Katashima, M; Matsushima, H; Miyahara, H; Sawamoto, T; Takusagawa, S; Tanaka, T; Tokuno, T; van Gelderen, M, 2014)	1.01
" Pharmacokinetic parameters were determined using non-compartmental methods."	( Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies. Amada, Y; Iitsuka, H; Katashima, M; Matsushima, H; Miyahara, H; Sawamoto, T; Takusagawa, S; Tanaka, T; Tokuno, T; van Gelderen, M, 2014)	0.73
"Mirabegron OCAS exhibits similar single- and multiple-dose pharmacokinetic characteristics and deviations from dose proportionality in healthy Japanese male subjects compared with those observed in non-Japanese (primarily Caucasian) subjects in previous studies."	( Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies. Amada, Y; Iitsuka, H; Katashima, M; Matsushima, H; Miyahara, H; Sawamoto, T; Takusagawa, S; Tanaka, T; Tokuno, T; van Gelderen, M, 2014)	2.17
"The objective of these studies was to evaluate the pharmacokinetic profile, safety, and tolerability of mirabegron, a β3-adrenoceptor agonist for the treatment of overactive bladder, including food effects (low- or high-fat meals) and sex, in healthy East Asian subjects."	( Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects. Iitsuka, H; Katashima, M; Sawamoto, T; Takusagawa, S; van Gelderen, M, 2015)	0.95
"In total, 5 pharmacokinetic studies of mirabegron were conducted in healthy East Asian subjects."	( Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects. Iitsuka, H; Katashima, M; Sawamoto, T; Takusagawa, S; van Gelderen, M, 2015)	1.01
" In Japanese subjects, a greater reduction in mirabegron Cmax and AUC0-∞ was observed after a low-fat meal compared with a high-fat meal."	( Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects. Iitsuka, H; Katashima, M; Sawamoto, T; Takusagawa, S; van Gelderen, M, 2015)	1
" Furthermore, the effects of food on the pharmacokinetic profiles appeared to be similar among the 3 populations tested in our studies."	( Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects. Iitsuka, H; Katashima, M; Sawamoto, T; Takusagawa, S; van Gelderen, M, 2015)	0.74
" Four phase 1 studies were conducted in healthy subjects to evaluate the potential for pharmacokinetic interactions between mirabegron and metformin, warfarin, digoxin, or a combination oral contraceptive (COC)."	( Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives. Groen-Wijnberg, M; Kerbusch, V; Krauwinkel, W; Meijer, J; Tretter, R; van Dijk, J; van Gelderen, M; Zhang, W, 2017)	0.93
" Pharmacokinetic parameters were determined by non-compartmental methods."	( Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives. Groen-Wijnberg, M; Kerbusch, V; Krauwinkel, W; Meijer, J; Tretter, R; van Dijk, J; van Gelderen, M; Zhang, W, 2017)	0.73
"This was the first study to construct a physiologically-based pharmacokinetic (PBPK) model for mirabegron which incorporates the overall elimination pathways of metabolism by cytochrome P450 (CYP) 3A4, uridine 5'-diphosphate-glucuronosyltransferase (UGT) 2B7, and butyrylcholinesterase (BChE) and renal excretion."	( Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase. Konishi, K; Minematsu, T; Nagasaka, Y; Tabata, K, 2019)	0.98
"We previously verified a physiologically based pharmacokinetic (PBPK) model for mirabegron in healthy subjects using the Simcyp Simulator by incorporating data on the inhibitory effect on cytochrome P450 (CYP) 2D6 and a multi-elimination pathway mediated by CYP3A4, uridine 5'-diphosphate-glucuronosyltransferase (UGT) 2B7 and butyrylcholinesterase (BChE)."	( Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. Konishi, K; Minematsu, T; Nagasaka, Y; Tabata, K, 2019)	0.97
" Potential drug-drug interactions (DDIs) following coadministration of these 2 overactive bladder treatments were estimated using physiologically based pharmacokinetic models, developed and verified by comparing predicted and observed pharmacokinetic profiles from clinical studies."	( Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron. Goosen, TC; Lin, J; Malhotra, B; Tse, S; Yamagami, H, 2019)	0.72
" This work describes the development and verification of physiologically-based pharmacokinetic (PBPK) models for the CYP2D6-sensitive substrate, nebivolol and the index CYP2D6 inhibitors, mirabegron and cinacalcet."	( Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions. Gardner, I; Khoshaein, N; Kilford, P; Southall, R, 2022)	1.13
"The exposure of nebivolol, cinacalcet and mirabegron predicted by the PBPK models was verified against pharmacokinetic data from 13, 3 and 9 clinical studies, respectively."	( Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions. Gardner, I; Khoshaein, N; Kilford, P; Southall, R, 2022)	1.2

Excerpt	Reference	Relevance
" In contrast to Spasmex, Mirabegron and Quercetin in combination with Testosterone and Estradiol contributed to stabilization of eNOS and nNOs expression already at early observation phases, and reduced the level of iNOS expression with its further disappearance in the later observation period."	( MORPHOLOGICAL ASSESSMENT OF NO-SYNTHASE DISTRIBUTION IN OVERACTIVE BLADDER AND STRESS URINE INCONTINENCE IN ANIMAL MODELS ADMINISTERED WITH EXPERIMENTAL PHARMACOCORRECTION REGIMENS. Iatsyna, O; Kostyev, F; Vernygorodskyi, S, 2018)	0.78
" Potential drug-drug interactions (DDIs) following coadministration of these 2 overactive bladder treatments were estimated using physiologically based pharmacokinetic models, developed and verified by comparing predicted and observed pharmacokinetic profiles from clinical studies."	( Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron. Goosen, TC; Lin, J; Malhotra, B; Tse, S; Yamagami, H, 2019)	0.72
" The performance of the PBPK models was verified by comparing the simulated results against reported human systemic exposure and clinical drug-drug interactions (DDIs) studies."	( Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions. Gardner, I; Khoshaein, N; Kilford, P; Southall, R, 2022)	0.93

Excerpt	Reference	Relevance
") and oral doses, absolute bioavailability (F), dose proportionality, sex differences and tolerability were assessed in 2 single-dose, open-label, randomized, parallel-group, cross-over studies in healthy men (exploratory Study 1, n = 12) and men and women (Study 2, n = 91)."	( Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder. Drogendijk, T; Eltink, C; Grunenberg, N; Iitsuka, H; Kerbusch, V; Kowalski, D; Lee, J; Matsushima, H; Meijer, J; Moy, S; Sawamoto, T; Schaddelee, M; van Gelderen, M; van Marle, S; Zhang, W, 2012)	0.62
" Involvement of saturable efflux transporters is indicated in oral bioavailability of mirabegron."	( The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Kashyap, M; Tyagi, P, 2013)	0.89
" Mirabegron extended release formulation shows dose-dependent oral bioavailability in humans, which is likely attributable to saturation of intestinal efflux abilities leading to higher absorption with higher doses."	( Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Iwatsubo, T; Kerbusch, V; Li, Q; Miyashita, A; Nemoto, H; Takahashi, Y; Takusagawa, S; Ushigome, F; Usui, T, 2013)	1.58
" Bioavailability studies were conducted in Wistar rats after oral administration of plain MBN dispersion, MBN-SLN, and MBN-PEG-SLN."	( Development and Optimization of Mirabegron Solid Lipid Nanoparticles as an Oral Drug Delivery for Overactive Bladder. Gambhire, M; Gambhire, V; Panchal, D; Raut, P, 2021)	0.9
"Thus, the study established that the oral bioavailability of MBN could be improved by the administration of MBN-PEG-SLN."	( Development and Optimization of Mirabegron Solid Lipid Nanoparticles as an Oral Drug Delivery for Overactive Bladder. Gambhire, M; Gambhire, V; Panchal, D; Raut, P, 2021)	0.9

Excerpt	Relevance	Reference
" dosing (7."	( Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder. Drogendijk, T; Eltink, C; Grunenberg, N; Iitsuka, H; Kerbusch, V; Kowalski, D; Lee, J; Matsushima, H; Meijer, J; Moy, S; Sawamoto, T; Schaddelee, M; van Gelderen, M; van Marle, S; Zhang, W, 2012)	0.62
" Excretion of unchanged mirabegron in urine over the 24-hour dosing interval (Ae(0-τ)%) increased from approximately 7% at 25 mg to 18% at 300 mg once daily in young subjects."	( Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Eltink, C; Kerbusch, V; Krauwinkel, W; Meijer, J; Schaddelee, M; Strabach, G; van Dijk, J; van Gelderen, M; van Marle, S, 2012)	0.97
"This study was designed to assess the effects of food on the pharmacokinetic properties of mirabegron OCAS in accordance with regulatory requirements to support dosing recommendations."	( Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults. Grunenberg, N; Keirns, J; Kerbusch, V; Kowalski, D; Lee, J; Moy, S; Sawamoto, T; van Gelderen, M; Zhang, W, 2013)	0.85
" Steady-state mirabegron pharmacokinetic parameters (50 and 100 mg mirabegron OCAS) were similar in 13 CYP2D6 poor, 40 intermediate, and 99 extensive metabolizers, whereas C max and AUC under the dosing interval τ of 24 h (AUCτ) were 30-47 % lower in 10 ultrarapid metabolizers."	( Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. Keirns, J; Kerbusch, V; Kowalski, D; Krauwinkel, W; Lee, J; Marion, A; Meijer, J; Moy, S; Roy, M; Sawamoto, T; Takusagawa, S; van Gelderen, M, 2013)	0.98
" Mirabegron accumulated twofold upon once-daily dosing relative to single-dose data."	( Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies. Amada, Y; Iitsuka, H; Katashima, M; Matsushima, H; Miyahara, H; Sawamoto, T; Takusagawa, S; Tanaka, T; Tokuno, T; van Gelderen, M, 2014)	1.64
" The secondary objective was to explore the dose-response relationship and the safety/tolerability compared with placebo and monotherapy."	( Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Abrams, P; Kay, R; Kelleher, C; Martina, R; Newgreen, D; Paireddy, A; Rechberger, T; Ridder, A; Staskin, D; van Maanen, R, 2015)	0.71
" Mirabegron accumulated 2- to 3-fold on once-daily dosing of multiple-dose relative to single-dose data."	( Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects. Iitsuka, H; Katashima, M; Sawamoto, T; Takusagawa, S; van Gelderen, M, 2015)	1.65
" The dosage of mirabegron was 50 mg per day."	( [Persistence in the treatment of overactive bladder (OAB) with Mirabegron in a multicentre clinical study]. Hanuš, T; Krhut, J; Martan, A; Mašata, J; Švabík, K, 2015)	1.01
" The dosage of Mirabegron was 50 mg per day in 162 patients, though for 44 of the patients the treatment was changed."	( [Cure effect and persistence of treatment with Mirabegron in patients with symptoms of overactive bladder: a multicentre clinical study]. Hanuš, T; Krhut, J; Martan, A; Mašata, J; Švabík, K; Zachoval, R, )	0.74
" Tolterodine ER was dosed at 4 mg for 8 weeks and mirabegron was dosed at 25 mg for 4 weeks then increased to 50 mg for the next 4 weeks."	( Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER). Fialkov, J; Gooch, K; Herschorn, S; Schermer, CR; Staskin, D; Tu, LM; Walsh, T, 2018)	0.96
" We also found that increasing value of total payment and increasing frequency of payments were both independently associated with increased odds of prescribing with a dose-response effect."	( The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Chang, SL; Dupree, JM; Kirk, PS; Modi, PK; Singer, EA; Wang, Y, 2018)	0.48
" A dose-response study was conducted in 6 pigs to select the highest intravenous dose of mirabegron without significant detrimental hemodynamic effect."	( Mirabegron, a Clinically Approved β3 Adrenergic Receptor Agonist, Does Not Reduce Infarct Size in a Swine Model of Reperfused Myocardial Infarction. Fernández-Jiménez, R; Galán-Arriola, C; García-Álvarez, A; García-Prieto, J; García-Ruiz, JM; Ibanez, B; Lobo-Gonzalez, M; Piñero, A; Pizarro, G; Rossello, X; Sánchez-González, J; Sanz-Rosa, D; Vilchez, JP, 2018)	2.15
" The OAB-q could detect dose-response relationships in some studies and demonstrated there were no significant differences across therapies from different drug classes."	( Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review. Johnston, KM; Lakzadeh, P; Walker, DR, 2019)	0.51
"A phase IV study comparing flexibly dosed mirabegron versus placebo in elderly patients with OAB and urgency incontinence."	( Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Engel, E; Herschorn, S; Kristy, RM; Schermer, CR; Staskin, D; Wagg, A, 2020)	1.09
"The purpose of the study was to characterize the PK of mirabegron in pediatric patients with neurogenic detrusor overactivity or idiopathic OAB, to provide a basis for a weight-based dosing algorithm, and to evaluate the safety, tolerability, and palatability/acceptability of the formulations."	( The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. Baka-Ostrowska, M; Bosman, B; Kjaeer, B; Passier, P; Rittig, S; Stroosma, O; Tannenbaum, S; Tøndel, C; Walle, JV, 2020)	1.06
" The finalized PK model used to characterize the pediatric PK of mirabegron will be utilized to develop a weight-based dosing algorithm."	( The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. Baka-Ostrowska, M; Bosman, B; Kjaeer, B; Passier, P; Rittig, S; Stroosma, O; Tannenbaum, S; Tøndel, C; Walle, JV, 2020)	1.05
"The present review provides an insight into the mechanism, pharmacokinetics, toxicokinetics, clinical trials and the development of various conventional and modified-release dosage forms of mirabegron for the treatment of overactive bladder syndrome."	( Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome. Mandpe, P; Prabhakar, B; Shende, P, 2020)	1.12
" The modified-release tablet dosage form of mirabegron appear to be a proficient and suitable replacement for antimuscarinics and revealed the tremendous potential to overcome the adverse effects of conventional antimuscarinic drugs like Oxybutyline chloride ER, Detrol LA, VESIcare, etc."	( Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome. Mandpe, P; Prabhakar, B; Shende, P, 2020)	1.19
"We conducted this meta-analysis to explore the tolerance of monotherapy with mirabegron (50 mg) on an overactive bladder, compared with a common dosage of anticholinergic agents."	( Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder: A systematic review and meta-analysis. Yang, J; Yang, Y; Yi, W, 2021)	1.19
" This could be associated with fewer side effects due to drug dosage reduction."	( Efficacy of overactive neurogenic bladder treatment: A systematic review of randomized controlled trials. Bapir, R; Bhatti, KH; Buchholz, N; Eliwa, A; García-Perdomo, HA; Gherabi, N; Hennessey, D; Magri, V; Mourmouris, P; Ouattara, A; Perletti, G; Philipraj, J; Stamatiou, K; Trinchieri, A, 2022)	0.72
"Green spectrofluorimetric methods have been adopted for the determination of Mirabegron (MG) in pure drug and pharmaceutical dosage form."	( Spectrofluorimetric methods for the determination of mirabegron by quenching tyrosine and L-tryptophan fluorophores: Recognition of quenching mechanism by stern volmer relationship, evaluation of binding constants and binding sites. Abdellatef, HE; Farid, NA; Sharaf, YA; Youssef, NF, 2023)	1.39
" All women with OAB received daily dosage of 50 mg of mirabegron for 12 weeks."	( Urinary beta 3-adrenoceptor as a diagnostic biomarker for overactive bladder in women. Chou, YC; Hsieh, WC; Huang, JY; Huang, TX; Huang, YH; Liang, CC; Lo, TS, 2023)	1.16

Role	Description
beta-adrenergic agonist	An agent that selectively binds to and activates beta-adrenergic receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
1,3-thiazoles
aromatic amide	An amide in which the amide linkage is bonded directly to an aromatic system.
ethanolamines
monocarboxylic acid amide	A carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Assay ID	Title	Year	Journal	Article
AID1238586	Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as decrease in mean blood pressure at 1 mg/kg, iv measured for 30 mins relative to control	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1218443	Drug recovery in healthy human plasma at 160 mg, po as single dose measured at 2 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1218445	Drug recovery in healthy human plasma at 160 mg, po as single dose measured at 8 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1276835	Increase in circulating free fatty acid level in iv infused Sprague-Dawley rat after 45 mins by liquid chromatography-tandem mass spectrometric analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.
AID1218410	Absolute oral bioavailability in rat at 30 mg/kg	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1238584	Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as decrease in heart rate at 1 mg/kg, iv measured for 30 mins relative to control	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1218441	Drug recovery in healthy human urine at 160 mg, po as single dose measured up to 48 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1218455	Terminal elimination phase half life in healthy human urine at 160 mg, po as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1238583	Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as increase in heart rate at 1 mg/kg, iv measured for 30 mins relative to control	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1481944	Cardiotoxicity in Sprague-Dawley rat assessed as increase in heart beat rate at 3 mg/kg, iv after 30 mins (Rvb = 1.8 +/- 0.9%)
AID1238588	Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as decrease in heart rate at 3 mg/kg, iv measured for 30 mins relative to control	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1481946	Cardiotoxicity in Sprague-Dawley rat assessed as increase in mean blood pressure at 3 mg/kg, iv after 30 mins (Rvb = 1 +/- 0.5%)
AID1218428	Renal clearance in healthy human plasma at 160 mg, po as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1218456	Drug recovery in healthy human urine at 160 mg, po as single dose measured up to 408 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1238592	Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as decrease in mean blood pressure at 1 mg/kg, iv measured for 30 mins relative to control in presence of 0.01 mg/kg, iv of alpha1A-AR antagonist silodosin	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1481942	Inhibition of CYP2D6 (unknown origin) at 10 uM relative to control
AID1276834	Increase in circulating glycerol level in iv infused Sprague-Dawley rat after 45 mins by liquid chromatography-tandem mass spectrometric analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.
AID1218413	Absolute oral bioavailability in dog at 1 mg/kg	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1481945	Cardiotoxicity in Sprague-Dawley rat assessed as decrease in heart beat rate at 3 mg/kg, iv after 30 mins (Rvb = 4.5 +/- 0.8%)
AID1218444	Drug recovery in healthy human plasma at 160 mg, po as single dose measured at 4 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1218426	Apparent oral clearance in healthy human plasma at 160 mg, po as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1481947	Cardiotoxicity in Sprague-Dawley rat assessed as decrease in mean blood pressure at 3 mg/kg, iv after 30 mins (Rvb = 5.4 +/- 1.9%)
AID1218452	Cmax in healthy human plasma at 160 mg, po as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1218451	Tmax in healthy human plasma at 160 mg, po as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1218412	Absolute oral bioavailability in dog at 0.5 mg/kg	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1238587	Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as increase in heart rate at 3 mg/kg, iv measured for 30 mins relative to control	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1218408	Absolute oral bioavailability in rat at 3 mg/kg	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1238589	Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as increase in mean blood pressure at 3 mg/kg, iv measured for 30 mins relative to control	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1238590	Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as decrease in mean blood pressure at 3 mg/kg, iv measured for 30 mins relative to control	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1218453	AUC (infinity) in healthy human plasma at 160 mg, po as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1238585	Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as increase in mean blood pressure at 1 mg/kg, iv measured for 30 mins relative to control	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1238591	Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as increase in heart rate at 1 mg/kg, iv measured for 30 mins relative to control in presence of 0.01 mg/kg, iv of alpha1A-AR antagonist silodosin	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1218411	Absolute oral bioavailability in dog at 0.25 mg/kg	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1218454	Terminal elimination phase half life in healthy human plasma at 160 mg, po as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1218409	Absolute oral bioavailability in rat at 10 mg/kg	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1218427	Apparent volume of distribution during terminal phase in healthy human plasma at 160 mg, po as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1218446	Drug recovery in healthy human plasma at 160 mg, po as single dose measured at 12 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
AID1346250	Human beta2-adrenoceptor (Adrenoceptors)	2007	The Journal of pharmacology and experimental therapeutics, May, Volume: 321, Issue:2	Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
AID1346297	Human beta3-adrenoceptor (Adrenoceptors)	2007	The Journal of pharmacology and experimental therapeutics, May, Volume: 321, Issue:2	Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
AID1346260	Human beta1-adrenoceptor (Adrenoceptors)	2007	The Journal of pharmacology and experimental therapeutics, May, Volume: 321, Issue:2	Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (0.55)	29.6817
2010's	342 (62.98)	24.3611
2020's	198 (36.46)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	131 (23.48%)	5.53%
Reviews	102 (18.28%)	6.00%
Case Studies	6 (1.08%)	4.05%
Observational	22 (3.94%)	0.25%
Other	297 (53.23%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (157)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Is Mirabegron 25 mg Safe and Effective in Treatment of Primary Nocturnal Enuresis as Regard Oral Desmopressin 120 mcg? [NCT05617664]		150 participants (Anticipated)	Interventional	2022-11-23	Recruiting
An Open-label, Randomized, 2-way Crossover Study to Evaluate the Pharmacokinetics of Mirabegron and Its Metabolites in Healthy Young and Elderly Male and Female Subjects [NCT01285596]	Phase 1	75 participants (Actual)	Interventional	2009-03-31	Completed
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence [NCT05806164]	Phase 4	432 participants (Anticipated)	Interventional	2023-06-06	Recruiting
Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study [NCT03600766]	Phase 2	50 participants (Anticipated)	Interventional	2018-08-01	Active, not recruiting
A Phase 1b, Randomized, Double-Masked, Parallel Group, Placebo Controlled Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects [NCT01284309]	Phase 1	321 participants (Actual)	Interventional	2010-11-30	Completed
A Phase 1, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Crossover Study to Evaluate the Effect of Repeat Oral Doses of Mirabegron on Cardiac Repolarization in Healthy Male and Female Adult Subjects [NCT01199523]	Phase 1	352 participants (Actual)	Interventional	2010-05-31	Completed
A Double-blind Two-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics (PK) of an Ethinyl Estradiol and Levonorgestrel Containing Combined Oral Contraceptive (COC) [NCT01297179]	Phase 1	30 participants (Actual)	Interventional	2008-10-31	Completed
Far Eastern Memorial Hospital [NCT03695822]	Phase 4	0 participants (Actual)	Interventional	2018-12-24	Withdrawn(stopped due to I did not pass the 2018 Ministry of Science and Technology research project subsidy, so I applied for the project to close the case.)
Comparative Study of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After Transurethral Resection of the Prostate - A Randomized Prospective Study [NCT03632772]	Phase 2	130 participants (Anticipated)	Interventional	2018-08-01	Recruiting
A Prospective, Non-interventional, Registry Study of Patients Initiating a Course of DrugTherapy for Overactive Bladder (OAB) [NCT02386072]		1,524 participants (Actual)	Observational	2015-01-05	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Comparison Clinical Study to Investigate the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron With Overactive Bladder Symptoms in Men [NCT02361502]	Phase 4	462 participants (Anticipated)	Interventional	2015-02-28	Recruiting
A Phase 1, Open-Label, Single Oral Dose Study to Assess the Safety, Pharmacokinetics and Effect of Food on the Pharmacokinetics of Mirabegron (YM178) in Healthy Volunteers [NCT01334905]	Phase 1	12 participants (Actual)	Interventional	2011-03-31	Completed
A Phase 1 Study to Evaluate the Effect of Steady State Solifenacin and Mirabegron on the Steady State Pharmacokinetics of Digoxin in Healthy Subjects [NCT02127034]	Phase 1	26 participants (Actual)	Interventional	2014-03-31	Completed
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania [NCT03602508]		5,589 participants (Actual)	Observational	2018-07-20	Completed
An Open-label, One-sequence, Two-arm Study to Evaluate the Effect of Steady State Concentrations of Mirabegron on the Pharmacokinetics of Solifenacin and to Evaluate the Effect of Steady State Concentrations of Solifenacin on the Pharmacokinetics of Mirab [NCT01297192]	Phase 1	41 participants (Actual)	Interventional	2009-03-31	Completed
An Exploratory Study Into the Mechanism of Mirabegron-induced Cardiovascular Effects in Healthy Male Subjects. [NCT01284868]	Phase 1	12 participants (Actual)	Interventional	2009-07-31	Completed
A Randomized, Double-blind, Parallel Group, Proof of Concept Study of YM178 in Comparison With Placebo and Tolterodine in Patients With Symptomatic Overactive Bladder [NCT01604928]	Phase 2	260 participants (Actual)	Interventional	2004-04-30	Completed
Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study [NCT05946902]	Phase 4	150 participants (Anticipated)	Interventional	2023-09-12	Recruiting
Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation: Prospective Randomized Controlled Trial [NCT05490082]	Phase 3	100 participants (Anticipated)	Interventional	2022-03-01	Recruiting
Effects of Sympathicomimetic Agonists on the Disease Course and Mutant Allele Burden in Patients With JAK2-mutated Myeloproliferative Neoplasms. A Multicenter Phase II Trial. [NCT02311569]	Phase 2	39 participants (Actual)	Interventional	2015-04-30	Completed
Effect of Mirabegron on Bladder Compliance ; a Prospective Paired Comparison of Mirabegron and Anticholinergics in Patients With Low Bladder Compliance [NCT05745584]		15 participants (Anticipated)	Interventional	2016-01-12	Active, not recruiting
Non-Interventional Study Assessing Quality of Life, Treatment Satisfaction, Resource Utilisation, and Persistence With Treatment in Overactive Bladder (OAB) Patients Prescribed Betmiga® - A Multicenter Non-interventional Post Authorisation Study (PAS) [NCT02320773]		863 participants (Actual)	Observational	2014-11-25	Completed
Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: an Open Label Pilot Study of Anticholinergic Agent vs. Mirabegron (MYRBETRIQ ®) to Evaluate Cognitive Impact and Efficacy [NCT03612401]	Early Phase 1	20 participants (Actual)	Interventional	2018-12-05	Completed
Mirabegron For Erectile Dysfunction [NCT02916693]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2017-08-01	Completed
A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects With Symptoms of Overactive Bladder [NCT00688688]	Phase 3	2,792 participants (Actual)	Interventional	2008-04-25	Completed
A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study to Evaluate the Urodynamics and Safety of YM178 in Male Subjects With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) [NCT00410514]	Phase 2	200 participants (Actual)	Interventional	2006-12-31	Completed
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Ur [NCT02757768]	Phase 4	715 participants (Actual)	Interventional	2016-06-13	Completed
Therapeutic Efficacy and Safety of Mirabegron , a β3-Adrenoceptor Agonist, Treatment on Patients With Overactive Bladder Syndrome in Taiwan - Predictive Factors for the First Line Use and the Dose Effectiveness Relationship [NCT03059134]	Phase 3	168 participants (Actual)	Interventional	2015-04-28	Completed
Identifying Responsible Signaling Pathway for Adrenergic Beta-3 Receptor Regulation in Human Subcutaneous White Adipose Tissue [NCT05634174]	Phase 1	40 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
Mirabegron and Physiological Function in Cold Environments - Aim 1 [NCT04766021]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2021-11-30	Completed
Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity [NCT05713799]	Phase 2	60 participants (Anticipated)	Interventional	2024-01-03	Not yet recruiting
Ureteral Stent-related Pain and Mirabegron (SPAM) Trial [NCT02095665]	Phase 4	22 participants (Actual)	Interventional	2014-01-01	Completed
Effectiveness of a Structured Intervention to Optimize Both the Use of Mirabegron, a β3 Receptor Agonist, and Facilitate Its Discontinuation: a Quasi-experimental Study [NCT03536494]		1,932 participants (Actual)	Interventional	2017-01-01	Completed
Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome [NCT05040984]		500 participants (Anticipated)	Observational	2021-04-30	Recruiting
Mirabegron for Female Patients With Overactive Bladder Syndrome: Comparison of Daytime and Nighttime Dosing [NCT03251300]	Phase 4	120 participants (Anticipated)	Interventional	2017-08-01	Recruiting
Comparative Effectiveness of Pelvic Floor Muscle Training, Mirabegron, and Trospium Among Older Women With Urgency Urinary Incontinence and High Fall Risk: a Feasibility Randomized Clinical Study [NCT05880862]	Early Phase 1	48 participants (Anticipated)	Interventional	2023-09-28	Recruiting
Sequencing and Combination of Mirabegron and Transcutaneous Tibial Nerve Stimulation (TTNS) in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial [NCT05188742]	Phase 4	180 participants (Anticipated)	Interventional	2021-11-10	Recruiting
A Multicentre, Open-Label, Single Dose, Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overacti [NCT02526979]	Phase 1	9 participants (Actual)	Interventional	2015-12-17	Completed
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics [NCT05051436]	Phase 4	96 participants (Anticipated)	Interventional	2021-12-13	Recruiting
A Phase 1, Open-Label, Randomized, Single Oral Dose, Three-Way Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Mirabegron [NCT00939757]	Phase 1	76 participants (Actual)	Interventional	2009-05-31	Completed
Impact of Beta 3 Agonist Mirabegron on Erectile Function on Patients With Benign Prostate Hyperplasia [NCT04503850]		100 participants (Anticipated)	Observational	2020-10-01	Not yet recruiting
Higher Neural and Cognitive Changes Following Anticholinergic Versus Beta 3 Agonist Versus Placebo Treatments in Female Patients With Overactive Bladder: a Multicenter Randomized Controlled Pilot Trial [NCT03817931]	Phase 4	30 participants (Anticipated)	Interventional	2019-08-05	Recruiting
A Pharmacokinetic Study in Healthy Non-elderly Male and Female Volunteers to Investigate the Effect of Food on the Pharmacokinetics of YM178 [NCT00965926]	Phase 1	72 participants (Actual)	Interventional	2009-07-31	Completed
Protocol for Specified Drug Use-results Survey of Betanis Tablets (for Patients With Coexisting Cardiovascular Disease) [NCT02570035]		316 participants (Actual)	Observational	2012-12-31	Completed
A Multi-centre Randomized, Placebo-controlled Trial of Mirabegron, a New beta3-adrenergic Receptor Agonist on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease [NCT02599480]	Phase 2	296 participants (Actual)	Interventional	2016-04-30	Active, not recruiting
Phase 4 Study of Cardiovascular Morbidity and Safety in Women Treated With Mirabegron for Overactive Bladder [NCT02622555]		221 participants (Actual)	Observational	2013-08-31	Completed
A Clinical Trial of Mirabegron for Overactive Bladder Symptoms in Patients With Parkinson Disease and Impaired Cognition [NCT02536976]	Phase 4	7 participants (Actual)	Interventional	2015-12-31	Completed
A Phase 1 Study to Evaluate the Effect of Steady State Solifenacin and Mirabegron on the Steady State Pharmacokinetics of Tamsulosin HCl in Healthy Male Subjects [NCT02169713]	Phase 1	20 participants (Actual)	Interventional	2014-05-31	Completed
THE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTS [NCT06124066]	Phase 4	42 participants (Actual)	Interventional	2022-07-01	Completed
Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder [NCT03558919]	Phase 4	81 participants (Actual)	Interventional	2017-01-01	Completed
A Prospective, Non-interventional, Registry Study of Patients Initiating Pharmacologic Therapy for Overactive Bladder in Taiwan, Korea and China [NCT03572231]		805 participants (Actual)	Observational	2018-07-19	Completed
An Open Label, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers. [NCT04485585]	Phase 1	36 participants (Actual)	Interventional	2020-07-20	Completed
Therapeutic Efficacy and Safety of Mirabegron , a β3-Adrenoceptor Agonist, Treatment on Patients With Overactive Bladder Syndrome in Taiwan - Comparison of Therapeutic Efficacy and Safety Between 25mg and 50mg [NCT03044912]	Phase 3	574 participants (Anticipated)	Interventional	2015-11-16	Recruiting
Mirabegron and Physiological Function in Cold Environments - Aim 1 [NCT05990387]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2023-07-19	Recruiting
A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis [NCT02787083]	Phase 3	9 participants (Actual)	Interventional	2016-08-31	Terminated(stopped due to Low enrollment)
Phase 2a Exploratory, Randomized, Double-blind, Parallel-group Study of ONO-8577 Compared to Combination of Solifenacin Succinate/ Mirabegron for Overactive Bladder [NCT03106623]	Phase 2	207 participants (Actual)	Interventional	2017-04-07	Completed
An Open-label, 2-Part, Phase 1 Clinical Trial to Evaluate Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults [NCT05992428]	Phase 1	36 participants (Anticipated)	Interventional	2023-08-22	Recruiting
An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents From 3 to Less Than 18 Years of Age With [NCT02751931]	Phase 3	91 participants (Actual)	Interventional	2016-06-17	Completed
Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Multiple Sclerosis (MIRROR) [NCT02086188]	Phase 4	28 participants (Actual)	Interventional	2014-05-31	Completed
Using Mirabegron to Increase Blood Pressure in Patients With Postural Orthostatic Tachycardia Syndrome [NCT06133075]	Phase 2	20 participants (Anticipated)	Interventional	2023-11-22	Not yet recruiting
The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury [NCT02893553]	Phase 2	41 participants (Actual)	Interventional	2016-12-31	Completed
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder [NCT00662909]	Phase 3	2,149 participants (Actual)	Interventional	2008-03-28	Completed
Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes: A Prospective Randomized Controlled Trial [NCT02540707]	Phase 4	113 participants (Actual)	Interventional	2015-09-08	Completed
Beta3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [NCT02775539]	Phase 2	80 participants (Anticipated)	Interventional	2016-06-30	Not yet recruiting
A Phase 1, Open-Label, Randomized, Parallel Dose Group Study to Assess the Pharmacokinetics of Mirabegron OCAS Formulations With Different Release Rates Versus IV Infusion in Healthy Volunteers [NCT00940121]	Phase 1	91 participants (Actual)	Interventional	2009-04-30	Completed
Beta 3 Agonist Treatment in Heart Failure-2 [NCT03926754]	Phase 2/Phase 3	56 participants (Actual)	Interventional	2017-01-23	Completed
A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder [NCT00689104]	Phase 3	2,336 participants (Actual)	Interventional	2008-04-28	Completed
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder [NCT00912964]	Phase 3	2,030 participants (Actual)	Interventional	2009-04-28	Completed
An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects [NCT00856570]	Phase 1	24 participants (Actual)	Interventional	2008-09-30	Completed
A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain [NCT05658874]	Phase 3	80 participants (Anticipated)	Interventional	2022-12-01	Recruiting
Long-term Study of YM178: Long Term Study of YM178 in Subjects With Overactive Bladder [NCT00840645]	Phase 3	204 participants (Actual)	Interventional	2008-12-31	Completed
A Phase 4, Open-label, Randomized, Prospective, Interventional Post-authorization Efficacy and Safety Study of Mirabegron 50 mg and 25 mg for the Treatment of Overactive Bladder in Chinese Subjects [NCT04562090]	Phase 4	249 participants (Actual)	Interventional	2021-01-06	Completed
Sympathomimetics and Sympatholytics in Type 2 Diabetes: Teaching Old Drugs New Tricks [NCT04823442]		9 participants (Actual)	Interventional	2021-01-21	Completed
The Activation of Brown and Beige Fat and Role in Insulin Sensitivity [NCT02919176]	Early Phase 1	39 participants (Actual)	Interventional	2016-09-01	Completed
Title: A Randomized Clinical Trial Comparing Percutaneous Tibial Nerve Stimulation in Combination With Mirabegron to Percutaneous Tibial Nerve Stimulation Plus Placebo in Women With Refractory OAB Symptoms [NCT04907032]	Phase 4	54 participants (Actual)	Interventional	2021-10-01	Completed
Phase III Study of YM178 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients With Overactive Bladder [NCT00966004]	Phase 3	1,139 participants (Actual)	Interventional	2009-07-31	Completed
A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Effect of Mild, Moderate and Severe Renal Impairment on the Pharmacokinetics of YM178 [NCT00750620]	Phase 1	33 participants (Actual)	Interventional	2008-09-30	Completed
A Phase 1, Open-Label, Drug Interaction Study to Evaluate the Effect of Repeat Doses of Rifampin on the Single-Dose Pharmacokinetics of Mirabegron (YM178) [NCT00776516]	Phase 1	24 participants (Actual)	Interventional	2008-10-31	Completed
A Phase 3, Double-blind, Randomized, Multicenter, Parallel Group, Placebo-controlled Sequential Dose Titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Pediatric Subjects From 5 to < 18 Years of Age With Overactive Bladder [NCT04641975]	Phase 3	26 participants (Actual)	Interventional	2021-03-15	Terminated(stopped due to Termination due to operational futility)
Long-Term Specified Drug Use-results Survey of Betanis Tablets [NCT01901120]		1,263 participants (Actual)	Observational	2012-10-31	Completed
To Explore the Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and Develop Its Urinary Biomarker [NCT04693897]		400 participants (Anticipated)	Observational [Patient Registry]	2021-03-01	Not yet recruiting
Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder [NCT01043666]	Phase 3	1,126 participants (Actual)	Interventional	2009-12-31	Completed
Beta 3 Agonist Treatment in Heart Failure [NCT01876433]	Phase 2	70 participants (Actual)	Interventional	2013-09-30	Completed
Drug Use-Results Survey of Betanis Tablets 25 and 50 mg [NCT01919047]		10,711 participants (Actual)	Observational	2012-04-30	Completed
Post-Marketing Study of Mirabegron - A Pharmacokinetic Study to Assess Drug-Drug Interaction Between Mirabegron and Tolterodine - [NCT01964183]	Phase 4	24 participants (Actual)	Interventional	2013-06-30	Completed
Evaluation of the Efficacy and Urodynamic Outcomes Between Intradetrusor onabotulinumtoxinA Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity [NCT05968885]	Phase 4	300 participants (Anticipated)	Interventional	2021-10-01	Recruiting
An Open-label, Parallel Group, Randomized, Two-sequence, Three-way Crossover Study to Assess the Relative Bioavailability of Solifenacin Succinate and Mirabegron Fixed-dose Combination Tablets Compared to Co-administration of Single Entity Tablets at Thre [NCT02010944]	Phase 1	72 participants (Actual)	Interventional	2012-09-30	Completed
Cognitive, Urinary, and Functional Trajectories of Older Women Using Pharmacologic Treatment Strategies for Urgency Incontinence [NCT05362292]	Phase 4	270 participants (Anticipated)	Interventional	2022-10-04	Recruiting
A Multicentre, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS Tablets in Pediatric Subjects From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Ov [NCT02211846]	Phase 1	34 participants (Actual)	Interventional	2014-09-21	Completed
Predictor for Re-treatment of Overactive Bladder Syndrome After Discontinuation of Mirabegron Treatment for Female Overactive Bladder Syndrome [NCT04550702]		120 participants (Actual)	Observational	2015-01-01	Completed
An Exploratory Open Label, Three-way Crossover Study to Compare the Pharmacokinetic Profiles of Three Different YM178 Modified Release (OCAS) Formulations Under Fasted and Fed Conditions With YM178 Immediate Release (IR) Formulation Under Fasted Condition [NCT01646294]	Phase 1	34 participants (Actual)	Interventional	2005-01-31	Completed
EFFICACY AND SAFETY OF COMBINATION THERAPY WITH β3-ADRENOCEPTOR AGONIST (MIRABEGRON) AND α-ADRENOCEPTOR ANTAGONIST (TAMSULOSIN) FOR TREATMENT OF OVERACTIVE BLADDER IN MALE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. [NCT02279615]	Phase 4	200 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron [NCT01340027]	Phase 2	1,307 participants (Actual)	Interventional	2011-03-29	Completed
Effect of Mirabegron on Promoting Brown Adipose Tissue Activation [NCT05779514]		20 participants (Anticipated)	Interventional	2022-08-18	Recruiting
Mirabegron And Ureteral Stent-related Pain (MAP) Trial [NCT04286152]	Phase 3	142 participants (Anticipated)	Interventional	2020-02-03	Recruiting
Pharmacological or Cold-induced Activation of Brown Adipose Tissue Metabolism [NCT02811289]		22 participants (Actual)	Interventional	2016-08-05	Completed
Assessment of Efficacy of Mirabegron, Solifenacin, Tadalafil 5mg and Combination Therapy in Female Patients With Overactive Bladder: A Double Blinded Prospective Randomized Placebo -Controlled Trial [NCT06184334]		300 participants (Actual)	Interventional	2022-09-14	Completed
A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Dose Ranging Study With the Beta-3 Agonist YM178 in Patients With Symptomatic Overactive Bladder [NCT00337090]	Phase 2	1,108 participants (Actual)	Interventional		Completed
Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms - A Multicenter, Randomized Study [NCT04420533]		150 participants (Actual)	Interventional	2020-06-05	Completed
Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study [NCT05452434]	Phase 4	600 participants (Anticipated)	Interventional	2022-07-15	Not yet recruiting
Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms: a Randomized Controlled Trial [NCT04325880]	Phase 3	240 participants (Anticipated)	Interventional	2021-12-01	Recruiting
A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin [NCT01489696]	Phase 1	48 participants (Actual)	Interventional	2010-08-31	Completed
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study in Patients With Symptomatic Overactive Bladder [NCT00527033]	Phase 2	842 participants (Actual)	Interventional	2007-09-30	Completed
An Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers [NCT01720212]	Phase 1	24 participants (Actual)	Interventional	2012-05-31	Completed
An Open Label Randomized, Single Dose, Three-way, Partial Replicate Bioequivalence Study to Determine the Bioequivalence of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg F [NCT05767632]	Phase 1	30 participants (Actual)	Interventional	2022-05-30	Completed
A Phase 1, Open-Label, Two-Period, One-Sequence Crossover Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Male and Female Adult Volunteers [NCT01476800]	Phase 1	24 participants (Actual)	Interventional	2006-07-31	Completed
An Open Label, One-sequence, Parallel Study to Compare the Single Dose Pharmacokinetics of YM178 in Healthy Poor or Extensive Metabolisers for CYP2D6 and to Assess the Effect of Multiple Doses of YM178 on the Metabolism of the Model Substrate Metoprolol [NCT01478490]	Phase 1	28 participants (Actual)	Interventional	2002-09-30	Completed
Double-blind, Randomized, Placebo-controlled, Dose-escalating, Exploratory Study to Investigate the Pharmacokinetics, Safety and Tolerability of Multiple Doses of YM178 OCAS-M in Healthy Young Male and Female Subjects and Healthy Elderly Male and Female S [NCT01478503]	Phase 1	96 participants (Actual)	Interventional	2005-05-31	Completed
A Single Dose, Open Label, Randomized, Two-period Cross Over Study in Healthy Male Subjects to Assess the Absolute Bioavailability of YM178 OCAS-M Formulation [NCT01478529]	Phase 1	12 participants (Actual)	Interventional	2006-02-28	Completed
An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of the CYP2D6 Substrate Desipramine in Healthy Subjects [NCT01478568]	Phase 1	28 participants (Actual)	Interventional	2008-10-31	Completed
The Effect of Mirabegron on Brown Adipose Tissue in Healthy Young White Caucasian and South Asian Men [NCT03012113]	Phase 4	20 participants (Anticipated)	Interventional	2016-06-30	Recruiting
Comparisons of the Impact of Beta-3 Agonist Versus Antimuscarinics on Psychological Distress, Sexual Function, Bladder Wall Thickness and Blood Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study. [NCT04023253]	Phase 3	120 participants (Anticipated)	Interventional	2019-08-01	Recruiting
A 8 Weeks, Randomized, Open Label, Parallel Group, Active Control Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB) [NCT06181591]	Phase 2	44 participants (Anticipated)	Interventional	2024-01-15	Not yet recruiting
Acupuncture Combined With Mirabegron in the Treatment of Overactive Bladder Syndrome: A Prospective Randomized Controlled Trial [NCT06181019]	Phase 1	75 participants (Actual)	Interventional	2021-12-01	Active, not recruiting
Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled Trial [NCT03412513]	Phase 4	144 participants (Anticipated)	Interventional	2017-07-17	Recruiting
The Therapeutic Effect of Beta-3 Agonist and Anti-muscarinic Agent on Overactive Bladder Among Sjogren's Syndrome Patient [NCT04909255]	Phase 4	50 participants (Anticipated)	Interventional	2021-03-23	Recruiting
[NCT02436889]	Phase 4	23 participants (Actual)	Interventional	2016-02-29	Completed
A Double Blind Placebo Control Trial of Mirabegron for Medical Expulsive Therapy and to Manage Stent Pain for Ureteral Stones(Protocol # 01-16-20-02) [NCT02744430]	Phase 2	33 participants (Actual)	Interventional	2017-07-22	Completed
Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue [NCT01783470]	Phase 2	15 participants (Actual)	Interventional	2013-02-28	Completed
Pilot Study: Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women, an Open Label Study With Dose Escalation [NCT02981459]	Phase 4	0 participants (Actual)	Interventional	2017-12-08	Withdrawn(stopped due to Withdrawn by Sponsor)
A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron Prolonged-Release Microgranula-Based Suspension in Children [NCT05621616]	Phase 3	10 participants (Anticipated)	Interventional	2023-06-26	Recruiting
An Open-label Study to Evaluate the Pharmacokinetics of YM178 After Single Oral Administration of 14C-labeled YM178 in Healthy Male Volunteers [NCT01651312]	Phase 1	4 participants (Actual)	Interventional	2003-01-31	Completed
An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of Digoxin in Healthy Subjects [NCT01663961]	Phase 1	25 participants (Actual)	Interventional	2008-09-30	Completed
A Study to Evaluate Pharmacokinetics of Mirabegron After Single and Multiple Oral Administration to Healthy Non-elderly Male and Female Chinese Subjects [NCT01747564]	Phase 1	24 participants (Actual)	Interventional	2012-08-31	Completed
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists [NCT03049462]	Phase 1	100 participants (Anticipated)	Interventional	2017-03-13	Recruiting
The Mechanism of Human Non-Shivering Thermogenesis and Basal Metabolic Rate [NCT01950520]	Phase 2	134 participants (Anticipated)	Interventional	2014-02-07	Recruiting
An Open Label Randomized, Single Dose, Three Way Three Sequence Two Treatment Partial Replicate Crossover Bioequivalence Study to Determine the Bioequivalence of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Indust [NCT04476966]	Phase 1	29 participants (Actual)	Interventional	2020-01-20	Completed
A Phase 4 Open-label, Randomized, Single Oral Dose, Two-way Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of Mirabegron in Healthy Chinese Subjects [NCT04501640]	Phase 4	24 participants (Actual)	Interventional	2020-09-21	Completed
A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO) [NCT02092181]	Phase 4	30 participants (Actual)	Interventional	2014-03-31	Completed
An Open Label Single Dose Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of YM178 Compared With Healthy Subjects [NCT01579461]	Phase 1	32 participants (Actual)	Interventional	2008-11-30	Completed
Mechanisms for Activation of Beige Adipose Tissue in Humans [NCT04666636]	Phase 2	65 participants (Anticipated)	Interventional	2020-12-07	Recruiting
Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study [NCT03411252]	Early Phase 1	5 participants (Actual)	Interventional	2018-02-15	Terminated(stopped due to inability to enroll)
Mirabegron and Urinary Urgency Incontinence: The Clinical Response and the Female Urinary Microbiome [NCT02495389]	Phase 4	84 participants (Actual)	Interventional	2015-01-28	Completed
Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder [NCT02476175]	Phase 3	35 participants (Actual)	Interventional	2013-04-30	Completed
A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subject [NCT02045862]	Phase 3	1,829 participants (Actual)	Interventional	2014-03-17	Completed
Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage [NCT05369351]	Phase 2	66 participants (Anticipated)	Interventional	2023-01-10	Not yet recruiting
Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women [NCT05604222]	Phase 4	120 participants (Anticipated)	Interventional	2023-03-01	Recruiting
A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy [NCT01638000]	Phase 3	1,887 participants (Actual)	Interventional	2012-06-12	Completed
Comparison of Electroacupuncture to Mirabegron on Symptoms of Overactive Bladder in Women Who Have Failed Anti-Cholinergic Therapy [NCT03087578]		0 participants (Actual)	Interventional	2017-07-01	Withdrawn(stopped due to Study never started)
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) [NCT02216214]	Phase 4	888 participants (Actual)	Interventional	2014-10-07	Completed
A Multicenter Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event. [NCT02468375]	Phase 4	434 participants (Actual)	Interventional	2015-06-30	Completed
A Double Blind, Randomized Placebo Controlled Trial Evaluating the Urodynamic and Clinical Efficacy of Mirabegron Among Neurogenic Bladder Patients [NCT02044510]	Phase 2/Phase 3	32 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Slow recruitment and small observed effect size)
Efficacy of Pharmacological Stimulation of Brown and White Fat in Lean and Obese Young Adults [NCT02354807]	Phase 2	20 participants (Anticipated)	Interventional	2015-10-31	Recruiting
Efficacy and Tolerability of Mirabegron Compared to Oxybutynin Chloride Immediate Release for Neurogenic Detrusor Overactivity in Persons With Chronic Spinal Cord Injury: A Randomized, Double-Blind, Controlled, Cross-Over Clinical Trial [NCT03187795]	Phase 2	62 participants (Anticipated)	Interventional	2019-04-03	Recruiting
Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS) [NCT02410135]		34 participants (Actual)	Observational	2015-04-30	Completed
Specified Drug Use-results Survey of Betanis Tablets in OAB Patients With Coexisting Glaucoma [NCT01898624]		300 participants (Actual)	Observational	2012-12-04	Completed
A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms [NCT01908829]	Phase 3	2,174 participants (Actual)	Interventional	2013-07-10	Completed
Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy With Antimuscarinics in Patients With Overactive Bladder Treated With Mirabegron [NCT02294396]	Phase 4	649 participants (Actual)	Interventional	2014-10-28	Completed
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monot [NCT01972841]	Phase 3	3,527 participants (Actual)	Interventional	2013-11-05	Completed
The Effects of Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Urinary Frequency, Urgency and Urge Incontinence [NCT06123364]		56 participants (Actual)	Interventional	2019-10-14	Completed
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB) [NCT02138747]	Phase 4	376 participants (Actual)	Interventional	2014-07-24	Completed
Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement [NCT02462837]	Phase 2	11 participants (Actual)	Interventional	2015-05-31	Terminated(stopped due to insufficient rate of accrual)
Safety and Efficacy of Mirabegron as Add-on Therapy in Patients With Overactive Bladder Treated With Solifenacin: A Postmarketing Open-label Study in Japan [NCT01745094]	Phase 4	223 participants (Actual)	Interventional	2012-10-01	Completed
A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyp [NCT02656173]	Phase 4	568 participants (Actual)	Interventional	2016-01-25	Completed
Does Mirabegron Increase the Body Heat Generated by the Nervous System [NCT06011265]	Early Phase 1	15 participants (Anticipated)	Interventional	2023-04-27	Recruiting
Prospective Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder [NCT02468830]	Phase 3	58 participants (Actual)	Interventional	2013-04-30	Completed
Vaginal Estradiol vs Oral Beta-3 Agonist for Treatment of Overactive Bladder Syndrome: A Single-Therapy, Double-Blind, Randomized Controlled Trial [NCT05221021]	Phase 4	152 participants (Anticipated)	Interventional	2022-10-01	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00410514 (18) [back to overview]	Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Total Score
NCT00410514 (18) [back to overview]	Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Storage Symptom Score
NCT00410514 (18) [back to overview]	Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)
NCT00410514 (18) [back to overview]	Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax)
NCT00410514 (18) [back to overview]	Change From Baseline to End of Treatment in Bladder Voiding Efficiency (BVE)
NCT00410514 (18) [back to overview]	Safety Assessed by Adverse Events (AEs), Electrocardiogram (ECG), Vital Signs, Physical Exam and Laboratory Tests
NCT00410514 (18) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptom (ICIQ MLUTS) Total Symptom Score
NCT00410514 (18) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptom (ICIQ MLUTS) Total Bother Score
NCT00410514 (18) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Lower Urinary Tract Symptom Quality of Life (ICIQ-LUTSqol) Symptom Score
NCT00410514 (18) [back to overview]	Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Urgency Episodes With Urgency Severity ≥ 3 Per 24 Hours
NCT00410514 (18) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Lower Urinary Tract Symptom Quality of Life (ICIQ-LUTSqol) Overall Symptom Interference of Life Score
NCT00410514 (18) [back to overview]	Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Postvoid Residual Volume (PVR)
NCT00410514 (18) [back to overview]	Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Patient Perception of Bladder Condition (PPBC)
NCT00410514 (18) [back to overview]	Change From Baseline to End of Treatment in Bladder Contractile Index (BCI)
NCT00410514 (18) [back to overview]	Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Voided Volume Per Micturition
NCT00410514 (18) [back to overview]	Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Micturitions Per 24 Hours
NCT00410514 (18) [back to overview]	Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
NCT00410514 (18) [back to overview]	Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Voiding Score
NCT00662909 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Health-related Quality of Life (HRQL) Total Score
NCT00662909 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Level of Urgency
NCT00662909 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Nocturia Episodes Per 24 Hours
NCT00662909 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Pads Used Per 24 Hours
NCT00662909 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Urgency Episodes (Grades 3 or 4) Per 24 Hours
NCT00662909 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT00662909 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Number of Non-study Related Visits to Physician
NCT00662909 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Symptom Bother Score
NCT00662909 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score
NCT00662909 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Mobility Score
NCT00662909 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score
NCT00662909 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Self-care Score
NCT00662909 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score
NCT00662909 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Patient Perception of Bladder Condition (PPBC)
NCT00662909 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Treatment Satisfaction on Visual Analog Scale (TS-VAS)
NCT00662909 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment
NCT00662909 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working
NCT00662909 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment
NCT00662909 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed
NCT00662909 (31) [back to overview]	Change From Baseline to Week 4, Week 8 and Week 12 in Mean Volume Voided Per Micturition
NCT00662909 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in the European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)
NCT00662909 (31) [back to overview]	Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours
NCT00662909 (31) [back to overview]	Change From Baseline to Week 8 and Week 12 in Mean Number of Incontinence Episodes Per 24 Hours
NCT00662909 (31) [back to overview]	Change From Baseline to Week 8 and Week 12 in Mean Number of Micturitions Per 24 Hours
NCT00662909 (31) [back to overview]	Percentage of Participants With ≥ 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and the Final Visit
NCT00662909 (31) [back to overview]	Percentage of Participants With Improvement in Patient Perception of Bladder Condition (PPBC) at Week 12 and Final Visit
NCT00662909 (31) [back to overview]	Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and the Final Visit
NCT00662909 (31) [back to overview]	Change From Baseline to End of Treatment (Final Visit) in Mean Number of Micturitions Per 24 Hours
NCT00662909 (31) [back to overview]	Change From Baseline to Final Visit in Mean Volume Voided Per Micturition
NCT00662909 (31) [back to overview]	Change From Baseline to Week 4 in Mean Number of Incontinence Episodes Per 24 Hours
NCT00662909 (31) [back to overview]	Change From Baseline to Week 4 in Mean Number of Micturitions Per 24 Hours
NCT00688688 (28) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score
NCT00688688 (28) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Mobility Score
NCT00688688 (28) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score
NCT00688688 (28) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Self-Care Score
NCT00688688 (28) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score
NCT00688688 (28) [back to overview]	Change From Baseline to Month 12 and Final Visit in Patient Perception of Bladder Condition (PPBC)
NCT00688688 (28) [back to overview]	Change From Baseline to Month 12 and Final Visit in Treatment Satisfaction-visual Analog Scale (TS-VAS)
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Health-related Quality of Life (HRQL) Total Score
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Level of Urgency
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Number of Incontinence Episodes Per 24 Hours
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Number of Micturitions Per 24 Hours
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Number of Nocturia Episodes Per 24 Hours
NCT00688688 (28) [back to overview]	Change From Baseline to Months 3, 6, 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed
NCT00688688 (28) [back to overview]	Change From Baseline to Months 3, 6, 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment
NCT00688688 (28) [back to overview]	Change From Baseline to Months 3, 6, 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment
NCT00688688 (28) [back to overview]	Change From Baseline to Months 3, 6, 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working
NCT00688688 (28) [back to overview]	Change From Baseline to Months 3, 6, 12 and Final Visit in Number of Non-study Related Visits to Physician
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in the Mean Number of Pads Used Per 24 Hours
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in the European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Symptom Bother Score
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Volume Voided Per Micturition
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours
NCT00688688 (28) [back to overview]	Percentage of Participants With Zero Incontinence Episodes at Months 1, 3, 6, 9 and 12 and the Final Visit
NCT00688688 (28) [back to overview]	Percentage of Participants With Improvement in Patient Perception of Bladder Condition (PPBC)
NCT00688688 (28) [back to overview]	Percentage of Participants With ≥ 50% Reduction in Incontinence Episodes at Months 1, 3, 6, 9 and 12 and the Final Visit
NCT00688688 (28) [back to overview]	Safety as Assessed by Adverse Events (AEs), Vital Signs, Laboratory Tests, Physical Examination and Electrocardiogram
NCT00688688 (28) [back to overview]	Number of Participants With and Severity of Treatment-emergent Adverse Events (TEAEs)
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Health-related Quality of Life (HRQL) Total Score
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Level of Urgency
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Nocturia Episodes Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Pads Used Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Urgency Episodes (Grades 3 or 4) Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Number of Non-study Related Visits to Physician
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Symptom Bother Score
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in the European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)
NCT00689104 (31) [back to overview]	Change From Baseline to Week 8 and Week 12 in Mean Number of Incontinence Episodes Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Week 8 and Week 12 in Mean Number of Micturitions Per 24 Hours
NCT00689104 (31) [back to overview]	Percentage of Participants With ≥ 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and the Final Visit
NCT00689104 (31) [back to overview]	Percentage of Participants With Improvement in Patient Perception of Bladder Condition (PPBC) at Week 12 and Final Visit
NCT00689104 (31) [back to overview]	Change From Baseline to End of Treatment (Final Visit) in Mean Number of Micturitions Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours
NCT00689104 (31) [back to overview]	Percentage of Participants With Zero Incontinence Episodes at Week 4, Week 8, Week 12 and the Final Visit
NCT00689104 (31) [back to overview]	Change From Baseline to Final Visit in Mean Volume Voided Per Micturition
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4 in Mean Number of Incontinence Episodes Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4 in Mean Number of Micturitions Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Mobility Score
NCT00689104 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score
NCT00689104 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Self-care Score
NCT00689104 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score
NCT00689104 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D)Anxiety/Depression Score
NCT00689104 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Patient Perception of Bladder Condition (PPBC)
NCT00689104 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Treatment Satisfaction on Visual Analog Scale (TS-VAS)
NCT00689104 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment
NCT00689104 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working
NCT00689104 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment
NCT00689104 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8 and Week 12 in Mean Volume Voided Per Micturition
NCT00912964 (39) [back to overview]	Change From Baseline to Week 8 and Week 12 in Mean Number of Micturitions Per 24 Hours
NCT00912964 (39) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Mobility Score
NCT00912964 (39) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score
NCT00912964 (39) [back to overview]	Percentage of Responders for Number of Grade 3 or 4 Urgency Episodes
NCT00912964 (39) [back to overview]	Change From Baseline to Week 4 in Mean Number of Micturitions Per 24 Hours
NCT00912964 (39) [back to overview]	Change From Baseline to Week 4 in Mean Number of Incontinence Episodes Per 24 Hours
NCT00912964 (39) [back to overview]	Change From Baseline to End of Treatment (Final Visit) in Mean Volume Voided Per Micturition
NCT00912964 (39) [back to overview]	Change From Baseline to End of Treatment (Final Visit) in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT00912964 (39) [back to overview]	Change From Baseline to End of Treatment (Final Visit) in Mean Number of Urgency Episodes (Grades 3 or 4) Per 24 Hours
NCT00912964 (39) [back to overview]	Change From Baseline to End of Treatment (Final Visit) in Mean Number of Micturitions Per 24 Hours
NCT00912964 (39) [back to overview]	Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours
NCT00912964 (39) [back to overview]	Change From Baseline to Week 4, Week 8 and Week 12 in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT00912964 (39) [back to overview]	Change From Baseline to Week 4, Week 8 and Week 12 in Mean Volume Voided Per Micturition
NCT00912964 (39) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Health-related Quality of Life (HRQL) Total Score
NCT00912964 (39) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Nocturia Episodes Per 24 Hours
NCT00912964 (39) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Pads Used Per 24 Hours
NCT00912964 (39) [back to overview]	Percentage of Responders for Mean Level of Urgency
NCT00912964 (39) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Number of Non-study Related Visits to Physician
NCT00912964 (39) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Symptom Bother Score
NCT00912964 (39) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in the European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)
NCT00912964 (39) [back to overview]	Change From Baseline to Week 8 and Week 12 in Mean Number of Incontinence Episodes Per 24 Hours
NCT00912964 (39) [back to overview]	Change From Baseline to End of Treatment (Final Visit) in Mean Level of Urgency
NCT00912964 (39) [back to overview]	Percentage of Participants With ≥ 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and the Final Visit
NCT00912964 (39) [back to overview]	Percentage of Participants With Improvement in Patient Perception of Bladder Condition (PPBC) at Week 12 and Final Visit
NCT00912964 (39) [back to overview]	Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and the Final Visit
NCT00912964 (39) [back to overview]	Summary of Baseline, Week 12 and Final Visit Change in Bladder Symptoms on the Clinician Global Impression Scale
NCT00912964 (39) [back to overview]	Summary of Baseline, Week 12 and Final Visit Change in Bladder Symptoms on the Patient Global Impression Scale
NCT00912964 (39) [back to overview]	Change From Baseline to Week 4, Week 8 and Week 12 in Mean Number of Urgency Episodes (Grades 3 or 4) Per 24 Hours
NCT00912964 (39) [back to overview]	Change From Baseline to Week 4, Week 8 and Week 12 in Mean Level of Urgency
NCT00912964 (39) [back to overview]	Summary of Baseline, Week 12 and Final Visit Change in Overall Condition on the Patient Global Impression Scale
NCT00912964 (39) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed
NCT00912964 (39) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment
NCT00912964 (39) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working
NCT00912964 (39) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment
NCT00912964 (39) [back to overview]	Change From Baseline to Week 12 and Final Visit in Treatment Satisfaction on Visual Analog Scale (TS-VAS)
NCT00912964 (39) [back to overview]	Change From Baseline to Week 12 and Final Visit in Patient Perception of Bladder Condition (PPBC)
NCT00912964 (39) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score
NCT00912964 (39) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Self-Care Score
NCT00912964 (39) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score
NCT01340027 (30) [back to overview]	Percentage of Participants With a Health-related Quality of Life Total Score Response
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Treatment Satisfaction on Visual Analog Scale (TS-VAS)
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Health-related Quality of Life (HRQL) Total Score
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment (EOT) in Mean Volume Voided Per Micturition
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Patient Perception of Bladder Condition (PPBC)
NCT01340027 (30) [back to overview]	Percentage of Participants With Deterioration in PPBC
NCT01340027 (30) [back to overview]	Percentage of Participants With Improvement in PPBC
NCT01340027 (30) [back to overview]	Percentage of Participants With Major Improvement in PPBC
NCT01340027 (30) [back to overview]	Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score
NCT01340027 (30) [back to overview]	Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Mobility Score
NCT01340027 (30) [back to overview]	Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score
NCT01340027 (30) [back to overview]	Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Self-care Score
NCT01340027 (30) [back to overview]	Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Level of Urgency
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Number of Incontinence Episodes Per 24 Hours
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Number of Micturitions Per 24 Hours
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Number of Nocturia Episodes Per 24-Hours
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Number of Pads Used Per 24 Hours
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Volume Voided Per Micturition
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Work Productivity and Activity Impairment (WPAI)
NCT01340027 (30) [back to overview]	Percentage of Participants With 50% Reduction in Incontinence Episodes
NCT01340027 (30) [back to overview]	Percentage of Participants With Zero Incontinence Episodes Post-baseline
NCT01340027 (30) [back to overview]	Percentage of Participants With a Symptom Bother Response
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)
NCT01340027 (30) [back to overview]	Percentage of Participants With a Micturition Response
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
NCT01638000 (47) [back to overview]	Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants With Major Improvement in PPBC: ≥2 Point Improvement at Week 12 and Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12
NCT01638000 (47) [back to overview]	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants With Improvement in Symptom Bother Score as Assessed by the OAB-q: ≥ 10 Points Improvement in OAB-q at Week 12 and Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants With Improvement in PPBC: ≥1 Point Improvement at Week 12 and Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants With Improvement in HRQoL Scales as Assessed by the OAB-q: ≥10 Points Improvement in OAB-q at Week 12 and Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants With 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period
NCT01638000 (47) [back to overview]	Number of Pads Used at 4, 8 and 12 Weeks of Treatment and at the Final Visit
NCT01638000 (47) [back to overview]	Number of Nocturia Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit
NCT01638000 (47) [back to overview]	Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit
NCT01638000 (47) [back to overview]	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)
NCT01638000 (47) [back to overview]	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Patient Perception of Bladder Condition (PPBC)
NCT01638000 (47) [back to overview]	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours
NCT01638000 (47) [back to overview]	Change From Baseline in Mean Number of Nocturia Episodes Per 24 Hours After 4, 8 and 12 Weeks of Treatment
NCT01638000 (47) [back to overview]	Change From Baseline in Mean Number of Pads Used Per 24 Hours After 4, 8 and 12 Weeks of Treatment
NCT01638000 (47) [back to overview]	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Level of Urgency
NCT01638000 (47) [back to overview]	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours
NCT01638000 (47) [back to overview]	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
NCT01638000 (47) [back to overview]	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours
NCT01638000 (47) [back to overview]	Number of Urgency Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit
NCT01638000 (47) [back to overview]	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT01638000 (47) [back to overview]	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction (TS)-Visual Analog Scale (VAS)
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction Questionnaire-Likert Scale
NCT01638000 (47) [back to overview]	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Total Health-Related Quality of Life (HRQoL) Score as Assessed by the OAB-q
NCT01745094 (15) [back to overview]	Number for Participants Who Achieved Normalization of the Number of Incontinence Episodes Per 24 Hours
NCT01745094 (15) [back to overview]	Change From Baseline in Postvoid Residual (PVR) Volume
NCT01745094 (15) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT01745094 (15) [back to overview]	Number for Participants Who Achieved Normalization of the Number of Micturitions Per 24 Hours
NCT01745094 (15) [back to overview]	Number for Participants Who Achieved Normalization of the Number of Urgency Episodes Per 24 Hours
NCT01745094 (15) [back to overview]	Change From Baseline in OAB-q SF Total HRQL Score
NCT01745094 (15) [back to overview]	Change From Baseline in OABSS Total Score
NCT01745094 (15) [back to overview]	Change From Baseline in Overactive Bladder Questionnaire Short Form (OAB-q SF) Severity Score
NCT01745094 (15) [back to overview]	Number of Participants Who Achieved Normalization for OABSS Total Score
NCT01745094 (15) [back to overview]	Change From Baseline in the Number of Incontinence Episodes Per 24 Hours
NCT01745094 (15) [back to overview]	Change From Baseline in the Number of Micturitions Per 24 Hours
NCT01745094 (15) [back to overview]	Change From Baseline in the Number of Nocturia Episodes Per Night
NCT01745094 (15) [back to overview]	Change From Baseline in the Number of Urge Incontinence Episodes Per 24 Hours
NCT01745094 (15) [back to overview]	Change From Baseline in the Number of Urgency Episodes Per 24 Hours
NCT01745094 (15) [back to overview]	Change From Baseline in the Volume Voided Per Micturition
NCT01783470 (1) [back to overview]	BAT Activity as Measured by 18F-FDG PET/CT
NCT01908829 (36) [back to overview]	Change From Baseline in Overactive Bladder Symptom (OAB-q) Symptom Bother Score
NCT01908829 (36) [back to overview]	Change From Baseline in Patient Perception Bladder Control (PPBC) Score
NCT01908829 (36) [back to overview]	Change From Baseline in Post Void Residual (PVR) Volume
NCT01908829 (36) [back to overview]	Change From Baseline in Treatment Satisfaction - Visual Analogue Scale (TS-VAS) Score
NCT01908829 (36) [back to overview]	Change From Baseline to Weeks 4, 8 & 12 in Mean Number of Incontinence Episodes Per 24 Hours
NCT01908829 (36) [back to overview]	Number of Incontinence Episodes Reported During the 3-Day Diary
NCT01908829 (36) [back to overview]	Number of Nocturia Episodes Reported Over 3-Day Diary
NCT01908829 (36) [back to overview]	Number of Pads Used During the 3-Day Diary
NCT01908829 (36) [back to overview]	Number of Participants in Each Category of Patient and Clinician Global Impression of Change Scales (PGIC and CGIC)
NCT01908829 (36) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01908829 (36) [back to overview]	Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Anxiety/Depression
NCT01908829 (36) [back to overview]	Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Pain/Discomfort
NCT01908829 (36) [back to overview]	Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Self-care
NCT01908829 (36) [back to overview]	Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Usual Activities
NCT01908829 (36) [back to overview]	Number of Participants With Change From Baseline to EoT in Euroqol European Quality of Life-5 Dimensions (EQ-5D) Subscale Score: Mobility
NCT01908829 (36) [back to overview]	Number of UI Episodes Reported During the 3-Day Diary
NCT01908829 (36) [back to overview]	Percentage of Participants With a Mean of at Least 8 Micturitions Per 24 Hours at Baseline and Less Than 8 Micturitions Per 24 Hours Postbaseline
NCT01908829 (36) [back to overview]	Percentage of Participants With at Least a 1-Point Improvement From Baseline in PPBC
NCT01908829 (36) [back to overview]	Percentage of Participants With at Least a 10-Point Improvement From Baseline in HRQL Total Score
NCT01908829 (36) [back to overview]	Percentage of Participants With at Least a 10-Point Improvement From Baseline in OAB-q Symptom Bother Score
NCT01908829 (36) [back to overview]	Percentage of Participants With Major (at Least 2-Point) Improvement From Baseline in PPBC
NCT01908829 (36) [back to overview]	Percentage of Participants With Zero Incontinence Episodes Postbaseline
NCT01908829 (36) [back to overview]	Percentage of Participants With at Least a 50% Decrease From Baseline in Mean Number of Incontinence Episodes Per 24 Hours
NCT01908829 (36) [back to overview]	Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours
NCT01908829 (36) [back to overview]	Change From Baseline to EoT in Corrected Micturition Frequency (CMF)
NCT01908829 (36) [back to overview]	Change From Baseline in Mean Number of Micturitions Per 24 Hours
NCT01908829 (36) [back to overview]	Change From Baseline in Mean Number of Nocturia Episodes
NCT01908829 (36) [back to overview]	Change From Baseline in Mean Number of Pads Per 24 Hours
NCT01908829 (36) [back to overview]	Change From Baseline in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours
NCT01908829 (36) [back to overview]	Change From Baseline in Mean Number of Urgency Incontinence (UI) Episodes Per 24 Hours
NCT01908829 (36) [back to overview]	Change From Baseline in Mean Volume Voided (MVV) Per Micturition
NCT01908829 (36) [back to overview]	Change From Baseline in OAB-q Health-Related Quality of Life (HRQL) Total Score
NCT01908829 (36) [back to overview]	Change From Baseline in OAB-q HRQL Subscale Score: Concern
NCT01908829 (36) [back to overview]	Change From Baseline in OAB-q HRQL Subscale Score: Coping
NCT01908829 (36) [back to overview]	Change From Baseline in OAB-q HRQL Subscale Score: Sleep
NCT01908829 (36) [back to overview]	Change From Baseline in OAB-q HRQL Subscale Score: Social Interaction
NCT01972841 (70) [back to overview]	Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Activity Impairment
NCT01972841 (70) [back to overview]	Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Impairment While Working
NCT01972841 (70) [back to overview]	Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Overall Work Impairment
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in DBP Peak/Trough Difference
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP)
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Pulse Rate (PR)
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in Mean 24-hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP)
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in Mean DBP in the Tmax Window
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in Mean PR in the Tmax Window
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in Mean SBP in the Time to Maximum Concentration (Tmax) Window
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in PR Peak/Trough Difference
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in SBP Peak/Trough Difference
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8 and 12 in Mean Number of Incontinence Episodes Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8 and 12 in Mean Number of Micturitions Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8 and 12 in Mean Volume Voided Per Micturition
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8 and 12 in the OAB-q Symptom Bother Score
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8 and 12 in TS-VAS
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Pads Used Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Incontinence Episodes
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Nocturia Episodes
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Pads Used
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Urgency Incontinence Episodes
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q Health-Related Quality of Life Questionnaire (HRQL) Total Score
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Concern
NCT01972841 (70) [back to overview]	Number of Incontinence-Free Days at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Sleep
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Social
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Patient Perception of Bladder Condition Questionnaire (PPBC)
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Postvoid Residual (PVR) Volume
NCT01972841 (70) [back to overview]	Maximum 1-hour Change From Time-matched Baseline in DBP at Weeks 4, 12 and EoT
NCT01972841 (70) [back to overview]	Maximum 1-hour Change From Time-matched Baseline in PR at Weeks 4, 12 and EoT
NCT01972841 (70) [back to overview]	Maximum 1-hour Change From Time-matched Baseline in SBP at Weeks 4, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Number of Incontinence-Free Days With < 8 Micturitions at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Number of Nocturia Episodes at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Number of Pads Used at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT01972841 (70) [back to overview]	Number of Urgency Incontinence Episodes at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Patient's Global Impression of Change (PGIC) Scale: Impression in Bladder Symptoms at Week 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants for Micturition Frequency Normalization at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q HRQL Total Score) at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q Symptom Bother Scale) at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q HRQL Total Score and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q Symptom Bother Scale and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants With ≥ 1 Point Improvement From Baseline in PPBC at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants With ≥ 10 Points Improvement From Baseline in HRQL Total Score at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants With ≥ 10 Points Improvement From Baseline in the OAB-q Symptom Bother Score at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants With Major (≥ 2 Points) Improvement From Baseline in PPBC at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 7 Diary Days at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	PGIC Scale: Impression in General Health at Week 12 and EoT
NCT01972841 (70) [back to overview]	Number of Incontinence Episodes at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Number of Days With < 8 Micturitions at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in Corrected Micturition Frequency
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in Mean Number of Micturitions Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in Mean Volume Voided Per Micturition
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in Treatment Satisfaction-Visual Analogue Scale (TS-VAS)
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Anxiety/Depression
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Pain/Discomfort
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Self-Care
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Usual Activities
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in European Quality of Life in 5 Dimensions (EQ-5D) Questionnaire Subscale Score: Mobility
NCT01972841 (70) [back to overview]	Change From Baseline to Week 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score: Percent Work Time Missed
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Coping
NCT02044510 (1) [back to overview]	Bladder Capacity
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Pads Used Per 24 Hours
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Sleep
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Coping
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Concern
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQL Subscale Score: Social
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Health-Related Quality of Life Questionnaire (HRQoL): Total Score
NCT02045862 (53) [back to overview]	Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 7 Diary Days at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With Micturition Frequency Normalization at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With Major (≥ 2 Points) Improvement From Baseline in PPBC at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With ≥ 10 Points Improvement From Baseline in the OAB-q Symptom Bother Score at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With ≥ 10 Points Improvement From Baseline in HRQoL Total Score at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With ≥ 1 Point Improvement From Baseline in PPBC at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants Who Were Triple Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, ≥ 10 Points Improvement on OAB-q Symptom Bother Scale and ≥1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants Who Were Double Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q Symptom Bother Scale) at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants Who Were Double Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q HRQL Total Score) at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants Who Were Double Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants in Each Category of PGIC Scale: Impression in General Health at Month 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants in Each Category of Patient's Global Impression of Change (PGIC) Scale: Impression in Bladder Symptoms at Month 12 and EoT
NCT02045862 (53) [back to overview]	Participants Who Were Triple Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, ≥ 10 Points Improvement on OAB-q HRQL Total Score and ≥ 1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Number of Urgency Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02045862 (53) [back to overview]	Number of Pads Used During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Number of Nocturia Episodes Reported During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Number of Incontinence-Free Days With < 8 Micturitions Per Day During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9 and 12 in the Patient's Assessment of TS-VAS
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9 and 12 in the OAB-q Symptom Bother Score
NCT02045862 (53) [back to overview]	Number of Incontinence-Free Days During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9 and 12 in Mean Number of Micturitions Per 24 Hours
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9 and 12 in Mean Number of Incontinence Episodes Per 24 Hours
NCT02045862 (53) [back to overview]	Change From Baseline to EoT in the Patient's Assessment of Treatment Satisfaction-Visual Analogue Scale (TS-VAS)
NCT02045862 (53) [back to overview]	Change From Baseline to EoT in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score
NCT02045862 (53) [back to overview]	Change From Baseline to EoT in Mean Volume Voided Per Micturition
NCT02045862 (53) [back to overview]	Change From Baseline to EoT in Mean Number of Micturitions Per 24 Hours
NCT02045862 (53) [back to overview]	Change From Baseline to EoT in Corrected Micturition Frequency
NCT02045862 (53) [back to overview]	Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours
NCT02045862 (53) [back to overview]	Number of Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Number of Days With < 8 Micturitions Per Day During the 7-Day Micturition Diary Period Prior to Each Visit (at Months 1, 3, 6, 9, 12 and EoT)
NCT02045862 (53) [back to overview]	Change From Baseline to Months 6, 12 in WPAI:SHP Score: Percent Overall Work Impairment
NCT02045862 (53) [back to overview]	Change From Baseline to Months 6, 12 in WPAI:SHP Score: Percent Activity Impairment
NCT02045862 (53) [back to overview]	Change From Baseline to Months 6, 12 and EoT in WPAI:SHP Score: Percent Impairment While Working
NCT02045862 (53) [back to overview]	Change From Baseline to Months 6, 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score: Percent Work Time Missed
NCT02045862 (53) [back to overview]	Change From Baseline to Months 3, 6 and 12 in Mean Volume Voided Per Micturition
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Postvoid Residual (PVR) Volume
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Patient Perception of Bladder Condition (PPBC)
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Urgency Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Pads Used During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Nocturia Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours
NCT02086188 (7) [back to overview]	Mean # of Incontinence Episodes/Day
NCT02086188 (7) [back to overview]	Subject Global Impression (Single Question)
NCT02086188 (7) [back to overview]	Qualiveen Questionnaire
NCT02086188 (7) [back to overview]	Overactive Bladder Symptom Composite Score (OAB-SCS) at Baseline vs. Titration Visit
NCT02086188 (7) [back to overview]	Overactive Bladder Symptom Composite Score (OAB-SCS) at Baseline vs. Final Visit
NCT02086188 (7) [back to overview]	Mean Volume Voided/Micturition
NCT02086188 (7) [back to overview]	Mean # of Micturitions/Day Based on Voiding Diaries
NCT02092181 (7) [back to overview]	Change in Mean Daily OAB-SCS Visit 3 vs Baseline
NCT02092181 (7) [back to overview]	Change in the Mean Daily Overactive Bladder-Symptom Composite Score.
NCT02092181 (7) [back to overview]	Change in Mean Number of Incontinence Episodes Per 24 Hours
NCT02092181 (7) [back to overview]	Non- Motor Symptoms Scale (NMSS)
NCT02092181 (7) [back to overview]	Overactive Bladder Questionnaire Symptom Severity Scale( OAB-q)
NCT02092181 (7) [back to overview]	Patient Perception of Bladder Condition
NCT02092181 (7) [back to overview]	Subjects Global Impression of Change
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Overall Assessment of Participant's Fulfillment of OAB Medication Expectations
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Overall Assessment of Interruption of Day-to-Day Life Due to OAB
NCT02138747 (13) [back to overview]	Change From Baseline to End of Treatment (EOT) in Mean Number of Incontinence Episodes Per 24 Hours
NCT02138747 (13) [back to overview]	Change From Baseline to End of Treatment (EOT) in Number of Micturitions Per 24 Hours
NCT02138747 (13) [back to overview]	Participants Tolerability Assessed by the Medication Tolerability Scale of the Overactive Bladder-Satisfaction (OAB-S) Questionnaire at the End of Treatment (EOT)
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Impact on Daily Living With OAB.
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: OAB Control
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Overall Assessment of Improvement in Day-to-Day Life Due to OAB Medication
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Overall Assessment of Willingness to Continue OAB Medication
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Overall Satisfaction With OAB Medication
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Satisfaction With OAB Control
NCT02138747 (13) [back to overview]	Number of Participants With Adverse Events
NCT02138747 (13) [back to overview]	Participants Preference Based on a 5-Point Scale at the End of Period 2 in Participants Who Completed at Least 14 Days of Study Drug in Both Study Treatment Periods.
NCT02216214 (25) [back to overview]	Change From Baseline in Post-void Residual Volume (PVR)
NCT02216214 (25) [back to overview]	Change From Baseline to End of Treatment (EOT) in Mean Number of Micturitions Per 24 Hours
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in Barthel Index of Daily Living Score
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in Mean Number of Incontinence Episodes Per 24 Hours
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in OAB-q HRQL Subscale Scores
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in Mean Volume Voided Per Micturition
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in Montreal Cognitive Assessment (MoCA) Score
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in OAB-q: Health Related Quality of Life (HRQL) Total Score
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in Overactive Bladder Questionnaire (OAB-q): Symptom Bother Score
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in Patient Perception of Bladder Condition (PPBC)
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in PPIUS
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in Treatment Satisfaction Visual Analog Scale (TS-VAS)
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in University of Alabama, Birmingham - Life Space Assessment (UAB-LSA)
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in Vulnerable Elder Survey-13 (VES-13) Score
NCT02216214 (25) [back to overview]	Change From to EOT in Mean Number of Nocturia Episodes Per 24 Hours
NCT02216214 (25) [back to overview]	Percentage of Participants Major (≥ 2-Point) Improvement From Baseline in PPBC
NCT02216214 (25) [back to overview]	Percentage of Participants Who Achieved Micturition Frequency Normalization
NCT02216214 (25) [back to overview]	Percentage of Participants With ≥ 10-Point Improvement From Baseline in OAB-q HRQL Subscales
NCT02216214 (25) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT02216214 (25) [back to overview]	Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours
NCT02216214 (25) [back to overview]	Percentage of Participants With ≥ 1-Point Improvement From Baseline in PPBC
NCT02216214 (25) [back to overview]	Percentage of Participants With Zero Incontinence Episodes Per 24 Hours
NCT02216214 (25) [back to overview]	Change From Baseline in Number of Incontinence Episodes Reported During 3-Day Diary Prior to Each Visit
NCT02216214 (25) [back to overview]	Change From Baseline to EOT in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Incontinence Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Micturitions Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Nocturia Episodes Per Night
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Urgency Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Volume Voided Per Micturition
NCT02294396 (16) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Urge Incontinence Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Number for Participants Who Achieved Normalization of the Mean Number of Incontinence Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Number for Participants Who Achieved Normalization of the Mean Number of Micturitions Per 24 Hours
NCT02294396 (16) [back to overview]	Number for Participants Who Achieved Normalization of the Mean Number of Urgency Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Number of Participants Who Achieved Normalization for OABSS Total Score
NCT02294396 (16) [back to overview]	Number of Participants Who Achieved Normalization of the Mean Number of Nocturia Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in OAB-q SF Total HRQL Score
NCT02294396 (16) [back to overview]	Change From Baseline in Overactive Bladder Questionnaire Short Form (OAB-q SF) Symptom Severity Score
NCT02294396 (16) [back to overview]	Change From Baseline in Overactive Bladder Symptom Score (OABSS) Total Score
NCT02294396 (16) [back to overview]	Change From Baseline in Postvoid Residual (PVR) Volume
NCT02436889 (5) [back to overview]	Change From Baseline in Trail Making Test, Trail A Score at 8 Weeks
NCT02436889 (5) [back to overview]	Change From Baseline in Urge Incontinence Episodes Per Day on a Voiding Diary at 8 Weeks.
NCT02436889 (5) [back to overview]	Change From Baseline in California Verbal Learning Test (CVLT) Score at 8 Weeks
NCT02436889 (5) [back to overview]	Change From Baseline in Short Physical Performance Battery (SPPB) Score at 8 Weeks
NCT02436889 (5) [back to overview]	Change From Baseline in Total Urinary Incontinence Frequency Measured by a Voiding Diary at 8 Weeks
NCT02462837 (6) [back to overview]	Improvement From Baseline in the Incontinence Symptom Severity Index (ISSI) in the Myrbetriq™ Group at the 1 Week Follow-up Compared to Placebo Group.
NCT02462837 (6) [back to overview]	Improvement From Baseline in the Incontinence Symptom Severity Index (ISSI) in the Myrbetriq™ Group at the 2 Week Follow-up Compared to Placebo Group.
NCT02462837 (6) [back to overview]	Improvement From Baseline on the Patient Global Impression of Severity (PGI-S) at the 2 Week Follow-up.
NCT02462837 (6) [back to overview]	Reduction in Pain Medicine Intake at the 2 Week Follow-up
NCT02462837 (6) [back to overview]	Reduction in Pain Medicine Intake at the 2 Week Follow-up
NCT02462837 (6) [back to overview]	Improvement in Pain and Discomfort Perception Using a 10 Point Visual Analog Scale for Pain Assessment (VAS) at the 1 and 2 Week Follow-up.
NCT02468830 (5) [back to overview]	Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron
NCT02468830 (5) [back to overview]	Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron
NCT02468830 (5) [back to overview]	Improved Quality of Life Using the Patient Perception of Bladder Condition (PPBC) Scale
NCT02468830 (5) [back to overview]	Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Mirabegron
NCT02468830 (5) [back to overview]	Number of Participants With Cardio Vascular Safety
NCT02476175 (5) [back to overview]	Number of Participants With Grade 2 or 3 Urgency Episodes as a Measure of Efficacy
NCT02476175 (5) [back to overview]	Response to Urinary Incontinence as a Composite Measure of Efficacy of add-on Mirabegron
NCT02476175 (5) [back to overview]	Number of Participants Showing Improved Quality of Life Using the Patient Perception of Bladder Condition Scale and Voiding Diaries
NCT02476175 (5) [back to overview]	Number of Participants Without Variation in Heart Rate
NCT02476175 (5) [back to overview]	Number of Participants With Cardio Vascular Safety
NCT02495389 (4) [back to overview]	Change in Urinary Distress Inventory (UDI)
NCT02495389 (4) [back to overview]	Change in Pelvic Organ Prolapse Distress Inventory (POPDI) Score
NCT02495389 (4) [back to overview]	Change in Overactive Bladder Questionnaire (OAB-q) Health Related Quality of Life (HRQL)
NCT02495389 (4) [back to overview]	Change in Colo-Rectal-Anal Distress Inventory (CRADI)
NCT02536976 (3) [back to overview]	Change in Montreal Cognitive Assessment Total Score
NCT02536976 (3) [back to overview]	Change in Unified Parkinson's Disease Rating Scale
NCT02536976 (3) [back to overview]	Change in Overactive Bladder Questionnaire Subscale Scores
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Total International Prostate Symptom Score (IPSS)
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Total Health-Related QoL (HRQoL) Scores as Assessed by the OAB-q
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Symptom Bother as Assessed by the Overactive Bladder Questionnaire (OAB-q)
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Postvoid Residual (PVR) Volume
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Mean Volume Voided Per Micturition
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Mean Number of Urgency Episodes Per 24 Hours
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Mean Number of Nocturia Episodes
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Mean Number of Incontinence Episodes Per 24 Hours
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Total Overactive Bladder Symptom Score (OABSS)
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Maximum Urine Flow Rate (Qmax)
NCT02656173 (16) [back to overview]	Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per 24 Hours
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in IPSS Subscale Scores
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in OABSS Subscale Scores
NCT02656173 (16) [back to overview]	Change From Baseline to Weeks 4, 8, 12 in Mean Number of Micturitions Per 24 Hours
NCT02656173 (16) [back to overview]	Number of Participants With Adverse Events
NCT02744430 (2) [back to overview]	Spontaneous Stone Passage Using Fisher's Exact Test
NCT02744430 (2) [back to overview]	Comparison of Pain Levels Between Treatment Groups Using the Wong-Baker Pain Rating Scale
NCT02751931 (31) [back to overview]	Number of Participants With Study Drug Acceptability for Oral Suspension at Week 24
NCT02751931 (31) [back to overview]	Number of Participants With Study Drug Acceptability for Oral Suspension at Week 52
NCT02751931 (31) [back to overview]	Number of Participants With Study Drug Acceptability for Tablets at Week 24
NCT02751931 (31) [back to overview]	Number of Participants With Study Drug Acceptability for Tablets at Week 4
NCT02751931 (31) [back to overview]	Number of Participants With Study Drug Acceptability for Tablets at Week 52
NCT02751931 (31) [back to overview]	Apparent Volume of Distribution After Non-intravenous Administration (Vz/F) of Mirabegron
NCT02751931 (31) [back to overview]	Change From Baseline in Maximum Cystometric Capacity (MCC) at Week 24
NCT02751931 (31) [back to overview]	Change From Baseline in Maximum Cystometric Capacity at Week 4
NCT02751931 (31) [back to overview]	Maximum Plasma Concentration (Cmax) of Mirabegron
NCT02751931 (31) [back to overview]	Plasma Concentration of Mirabegron at the End of a Dosing Interval at Steady State (Ctrough)
NCT02751931 (31) [back to overview]	Time to Reach Maximum Plasma Concentration of Mirabegron Following Drug Administration (Tmax)
NCT02751931 (31) [back to overview]	Change From Baseline in Average Catheterized Volume Per Catheterization
NCT02751931 (31) [back to overview]	Change From Baseline in Average Morning Catheterized Volume
NCT02751931 (31) [back to overview]	Change From Baseline in Bladder Compliance (ΔV/ΔP)
NCT02751931 (31) [back to overview]	Change From Baseline in Detrusor Pressure at End of Filling
NCT02751931 (31) [back to overview]	Change From Baseline in Filling Bladder Volume Until First Overactive Detrusor Contraction (> 15 cm H20)
NCT02751931 (31) [back to overview]	Change From Baseline in Filling Bladder Volume Until First Overactive Detrusor Contraction (> 15 cm H20): Paired T-test
NCT02751931 (31) [back to overview]	Change From Baseline in Filling Bladder Volume Until First Overactive Detrusor Contraction (> 15 cm H20): Wilcoxon Signed-rank Test Updated Analysis
NCT02751931 (31) [back to overview]	Change From Baseline in Maximum Catheterized Daytime Volume (MCDV)
NCT02751931 (31) [back to overview]	Change From Baseline in Maximum Catheterized Volume
NCT02751931 (31) [back to overview]	Change From Baseline in Mean Number of Leakage Episodes Per Day
NCT02751931 (31) [back to overview]	Change From Baseline in Mean Number of Leakage Episodes Per Day: Updated Analysis
NCT02751931 (31) [back to overview]	Change From Baseline in Number of Dry Days Per 7 Days (Day and Night Time)
NCT02751931 (31) [back to overview]	Change From Baseline in Number of Overactive Detrusor Contractions (> 15 cm H20) Until End of Filling
NCT02751931 (31) [back to overview]	Change From Baseline in Patient Global Impression of Severity Scale (PGI-S)
NCT02751931 (31) [back to overview]	Change From Baseline in Pediatric Incontinence Questionnaire (PIN-Q) Score
NCT02751931 (31) [back to overview]	Apparent Total Clearance of Mirabegron From Plasma After Oral Administration (CL/F)
NCT02751931 (31) [back to overview]	Number of Participants With Study Drug Acceptability for Oral Suspension at Week 4
NCT02751931 (31) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT02751931 (31) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC24) for Mirabegron
NCT02751931 (31) [back to overview]	Number of Participants With Clinician Global Impression of Change (CGI-C)
NCT02757768 (21) [back to overview]	Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per Day
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Total Urgency and Frequency Score (TUFS)
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Treatment Satisfaction Visual Analog Scale (TS-VAS)
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, and Week 12 in Mean Number of Micturitions Per Day
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in European Quality of Life in 5 Dimensions and 5 Levels (EQ-5D-5L Questionnaire) Utilities
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in HRQL Subscale Coping Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in HRQL Subscale Sleep Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in HRQL Subscale Social Interaction Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in International Prostate Symptom Score (IPSS) Total Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in IPSS Subscale Quality of Life (QoL) Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in IPSS Subscale Voiding Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Number of Incontinence Episodes Per Day
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per Day
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12, and EoT in IPSS Subscale Storage Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in HRQL Subscale Concern Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Total Health Related Quality of Life (HRQL) Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Symptom Bother Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Patient Perception of Bladder Condition (PPBC)
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Volume Voided Per Micturition
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Number of Urgency Incontinence Episodes Per Day
NCT02787083 (2) [back to overview]	Number of Participants With Interstitial Cystitis Symptom Improvement
NCT02787083 (2) [back to overview]	Number of Participants With Improvement in Incontinence Episodes
NCT02916693 (10) [back to overview]	Health Related Quality of Life as Assessed by the OAB Questionnaire
NCT02916693 (10) [back to overview]	Health Related Quality of Life as Assessed by the OAB Questionnaire
NCT02916693 (10) [back to overview]	Health Related Quality of Life as Assessed by the OAB Questionnaire
NCT02916693 (10) [back to overview]	Health Related Quality of Life as Assessed by the OAB Questionnaire
NCT02916693 (10) [back to overview]	Erectile Function Assessed by IIEF Questionnaire
NCT02916693 (10) [back to overview]	Health Related Quality of Life as Assessed by the OAB Questionnaire
NCT02916693 (10) [back to overview]	Erectile Function Assessed by IIEF Questionnaire
NCT02916693 (10) [back to overview]	Erectile Function Assessed by IIEF Questionnaire
NCT02916693 (10) [back to overview]	Erectile Function Assessed by IIEF Questionnaire
NCT02916693 (10) [back to overview]	Erectile Function Assessed by IIEF Questionnaire
NCT04501640 (4) [back to overview]	Maximum Concentration (Cmax) For Mirabegron
NCT04501640 (4) [back to overview]	Number of Participants With Adverse Events (AE)
NCT04501640 (4) [back to overview]	Area Under The Concentration-Time Curve (AUC) From The Time of Dosing Extrapolated to Time Infinity (AUCinf) For Mirabegron
NCT04501640 (4) [back to overview]	Area Under The Concentration-Time Curve (AUC) From The Time of Dosing to The Last Measurable Concentration (AUClast) For Mirabegron
NCT04562090 (9) [back to overview]	Change From Baseline (CFB) to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg Group
NCT04562090 (9) [back to overview]	Change From Baseline to Week 12 in Post Void Residual (PVR) Volume
NCT04562090 (9) [back to overview]	Number of Participants With Treatment Emergent Adverse Events
NCT04562090 (9) [back to overview]	Change From Baseline in Mean Number of Daytime Incontinence Episodes Per 24 Hours
NCT04562090 (9) [back to overview]	Change From Baseline in Mean Number of Grade 3 or 4 Patient Perception of Intensity of Urgency Scale (PPIUS) Urgency Episodes Per 24 Hours
NCT04562090 (9) [back to overview]	Change From Baseline in Mean Number of Micturition Per 24 Hours
NCT04562090 (9) [back to overview]	Change From Baseline in Mean Number of Nighttime Incontinence Episodes Per 24 Hours
NCT04562090 (9) [back to overview]	Change From Baseline in Mean Number of Urge Incontinence Episodes Per 24 Hours
NCT04562090 (9) [back to overview]	Change From Baseline in OAB Symptom Score (OABSS)
NCT04641975 (14) [back to overview]	Change From Baseline to Week 12/EoT in Mean Number of Micturitions Per 24 Hours for Age Group 5 to <12 Years
NCT04641975 (14) [back to overview]	Change From Baseline in Post Void Residual (PVR) Volume
NCT04641975 (14) [back to overview]	Change From Baseline in Post Void Residual (PVR) Volume
NCT04641975 (14) [back to overview]	Change From Baseline to Week 12/EoT in Maximum Volume Voided (MVV) for Age Group 5 to <12 Years
NCT04641975 (14) [back to overview]	Change From Baseline to Week 12/EoT in Mean Number of Daytime Incontinence Episodes Per 24 Hours for Age Group 5 to <12 Years
NCT04641975 (14) [back to overview]	Change From Baseline to Week 12/EoT in Mean Number of Daytime Micturitions Per 24 Hours for Age Group 5 to <12 Years
NCT04641975 (14) [back to overview]	Change From Baseline to Week 12/EoT in Mean Number of Nighttime Incontinence Episodes Per 24 Hours for Age Group 5 to <12 Years
NCT04641975 (14) [back to overview]	Change From Baseline to Week 12/EoT in Mean Volume Voided Per 24 Hours for Age Group 5 to <12 Years
NCT04641975 (14) [back to overview]	Change From Baseline to Week 12/EoT in Number of Dry (Incontinence-free) Days Per 7 Days for Age Group 5 to <12 Years
NCT04641975 (14) [back to overview]	Number of Participants With Study Drug Acceptability and Palatability for Oral Suspension
NCT04641975 (14) [back to overview]	Number of Participants With Study Drug Acceptability and Palatability for Tablets
NCT04641975 (14) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
NCT04641975 (14) [back to overview]	PK of Mirabegron in Plasma: Concentration Immediately Prior to Dosing (Ctrough)
NCT04641975 (14) [back to overview]	PK of Mirabegron in Plasma: Concentration Immediately Prior to Dosing (Ctrough)
NCT04907032 (4) [back to overview]	Change in Symptom Distress as Measured by the Urinary Distress Index (UDI-6) Questionnaire Pre- (Baseline Measure) vs. Post-treatment (Post-trial Measure)
NCT04907032 (4) [back to overview]	Change in the Number of UUI Episodes Over a 3-day Voiding Diary Pre- vs. Post-treatment. This Includes a Baseline Measure Pre-trial and a Pos-trial Measure in 12 Weeks
NCT04907032 (4) [back to overview]	Change in UUI (Urge Urinary Incontinence)/OAB (Overactive Bladder) Quality of Life as Measured by the Incontinence Impact Questionnaire Short Form (IIQ-7) Questionnaire Pre- (Baseline Measure) vs. Post-treatment (Post-trial Measure in 12 Weeks)
NCT04907032 (4) [back to overview]	Change in UUI (Urge Urinary Incontinence)/OAB (Overactive Bladder) Quality of Life as Measured by the Overactive Bladder Questionnaire-Short Form (OAB-q SF) Questionnaire Pre- (Baseline Measure) vs. Post-treatment (Post-trial Measure)

Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Total Score

"The IPSS is a validated global questionnaire used to assess the degree of bother from benign prostatic hyperplasia symptoms and is based on the answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic).~Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate." (NCT00410514)
Timeframe: Baseline and Weeks 1, 4, 8 and 12

Intervention	scores on a scale (Least Squares Mean)
	Change from Baseline at Week 1 [N=63; 63; 57]	Change from Baseline at Week 4 [N=63; 62; 58]	Change from Baseline at Week 8 [N=62; 63; 56]	Change from Baseline at Week 12 [N=58; 61; 52]	Change from Baseline at EOT [N=63; 64; 58]
Mirabegron 100 mg	-1.6	-4.4	-5.3	-4.8	-4.8
Mirabegron 50 mg	-2.4	-5.2	-6.3	-6.3	-6.2
Placebo	-1.7	-4.0	-5.0	-5.2	-5.0

Intervention	participants (Number)
	Adverse events	Mild intensity adverse events	Moderate intensity adverse events	Severe intensity adverse events	Drug-related adverse events	Serious adverse events	AEs leading to study drug discontinuation	Deaths
Mirabegron 100 mg	34	20	14	0	11	0	2	0
Mirabegron 50 mg	28	16	10	2	5	0	1	0
Placebo	28	17	7	4	8	0	2	0

Intervention	scores on a scale (Least Squares Mean)
	Change from Baseline at Week 4 [N=60; 60; 58]	Change from Baseline at Week 8 [N=61; 61; 56]	Change from Baseline at Week 12 [N=58; 60; 53]	Change from Baseline at EOT [N=62; 61; 58]
Mirabegron 100 mg	-3.5	-4.9	-5.4	-5.5
Mirabegron 50 mg	-4.0	-5.1	-4.9	-4.8
Placebo	-2.8	-3.9	-4.2	-3.9

Intervention	scores on a scale (Least Squares Mean)
	Change from Baseline at Week 4 [N=58; 53; 56]	Change from Baseline at Week 8 [N=57; 57; 53]	Change from Baseline at Week 12 [N=54; 53; 51]	Change from Baseline at EOT [N=60; 57; 58]
Mirabegron 100 mg	-10.0	-19.3	-17.4	-18.6
Mirabegron 50 mg	-13.6	-21.9	-19.3	-20.1
Placebo	-7.5	-11.6	-15.1	-14.0

Intervention	scores on a scale (Least Squares Mean)
	Change from Baseline at Week 4 [N=41; 37; 33]	Change from Baseline at Week 8 [N=39; 36; 31]	Change from Baseline at Week 12 [N=40; 30;26]	Change from Baseline at EOT [N=47; 40; 36]
Mirabegron 100 mg	-3.1	-5.7	-5.7	-5.0
Mirabegron 50 mg	-4.1	-6.4	-6.9	-6.9
Placebo	-3.2	-4.8	-4.7	-4.8

Intervention	Urgency episodes (Least Squares Mean)
	Change from Baseline at Week 1 [N=63; 64; 57]	Change from Baseline at Week 4 [N=63; 64; 58]	Change from Baseline at Week 8 [N=62; 63; 57]	Change from Baseline at Week 12 [N=62; 63; 54]	Change from Baseline at EOT [N=63; 64; 58]
Mirabegron 100 mg	-0.60	-0.95	-0.98	-0.90	-0.93
Mirabegron 50 mg	-0.81	-1.13	-1.43	-1.65	-1.60
Placebo	0.09	-0.11	-0.35	-0.33	-0.33

Intervention	scores on a scale (Least Squares Mean)
	Change from Baseline at Week 4 [N=61; 62; 58]	Change from Baseline at Week 8 [N=60; 63; 57]	Change from Baseline at Week 12 [N=59; 61; 53]	Change from Baseline at EOT [N=62; 63; 58]
Mirabegron 100 mg	-1.0	-1.7	-1.9	-1.9
Mirabegron 50 mg	-1.2	-1.7	-2.1	-2.0
Placebo	-0.4	-0.9	-1.1	-1.1

Intervention	mL (Least Squares Mean)
	Change from Baseline at Week 1 [N=63; 66; 63]	Change from Baseline at Week 4 [N=63; 67; 63]	Change from Baseline at Week 8 [N=62; 67; 61]	Change from Baseline at Week 12 [N=59; 63; 57]	Change from Baseline at EOT [N=64; 70; 65]
Mirabegron 100 mg	0.51	8.63	-3.71	33.22	30.77
Mirabegron 50 mg	-2.93	-1.03	5.11	21.13	17.89
Placebo	-8.10	1.08	-9.92	4.65	0.55

Intervention	Incontinence episodes (Least Squares Mean)
	Change from Baseline at Week 1 [N=9; 18; 13]	Change from Baseline at Week 4 [N=9; 18; 13	Change from Baseline at Week 8 [N=9; 17; 13]	Change from Baseline at Week 12 [N=9; 17; 13]	Change from Baseline at EOT [N=9; 18; 13]
Mirabegron 100 mg	-0.97	-1.60	-2.31	-2.03	-1.98
Mirabegron 50 mg	-0.18	-0.42	-0.70	-0.91	-0.89
Placebo	-1.16	-0.99	-0.77	-0.98	-0.96

Intervention	Scores on a scale (Least Squares Mean)
	Week 4 [N= 352; 345; 335]	Week 8 [N= 324; 321; 322]	Week 12 [N= 315; 308; 318]	Final Visit (LOCF) [N= 355; 350; 344]
Mirabegron 100 mg	13.7	17.0	17.5	17.3
Mirabegron 50 mg	12.1	14.7	15.2	14.8
Placebo	9.2	11.4	11.1	10.7

Intervention	Scores on a scale (Least Squares Mean)
	Week 4 [N= 430; 421; 408]	Week 8 [N= 393; 393; 389]	Week 12 [N= 382; 377; 374]	Final Visit (LOCF) [N= 432; 425; 411]
Mirabegron 100 mg	-0.18	-0.21	-0.21	-0.21
Mirabegron 50 mg	-0.12	-0.17	-0.18	-0.19
Placebo	-0.08	-0.10	-0.09	-0.08

Intervention	Nocturia episodes (Least Squares Mean)
	Week 4 [N= 366; 345; 353]	Week 8 [N= 333; 324; 340]	Week 12 [N= 323; 311; 328]	Final Visit (LOCF) [N= 366; 348; 356]
Mirabegron 100 mg	-0.40	-0.55	-0.58	-0.57
Mirabegron 50 mg	-0.43	-0.54	-0.59	-0.57
Placebo	-0.29	-0.24	-0.32	-0.38

Intervention	pads (Least Squares Mean)
	Week 4 [N= 176; 165; 156]	Week 8 [N= 159; 154; 152]	Week 12 [N= 152; 145; 147]	Final Visit (LOCF) [N= 176; 166; 159]
Mirabegron 100 mg	-0.76	-1.03	-1.09	-1.06
Mirabegron 50 mg	-0.77	-0.96	-1.04	-1.03
Placebo	-0.40	-0.56	-0.63	-0.63

Intervention	Urgency episodes (Least Squares Mean)
	Week 4 [N= 430; 420; 408]	Week 8 [N= 393; 392; 389]	Week 12 [N= 382; 376; 374]	Final Visit (LOCF) [N= 432; 424; 411]
Mirabegron 100 mg	-1.45	-1.80	-1.79	-1.76
Mirabegron 50 mg	-1.03	-1.58	-1.63	-1.57
Placebo	-0.75	-0.91	-0.86	-0.82

Intervention	Urgency incontinence episodes (Least Squares Mean)
	Week 4 [N=319; 294; 288]	Week 8 [N=291; 273; 278]	Week 12 [N= 278; 264; 265]	Final Visit (LOCF) [N= 319; 297; 291]
Mirabegron 100 mg	-1.05	-1.44	-1.45	-1.45
Mirabegron 50 mg	-1.09	-1.23	-1.32	-1.32
Placebo	-0.62	-0.81	-0.94	-0.89

Intervention	Physician visits (Mean)
	Week 4 [N= 429; 422; 405]	Week 8 [N= 392; 389; 389]	Week 12 [N= 381; 377; 381]	Final Visit (LOCF) [N= 430; 422; 410]
Mirabegron 100 mg	0.0	0.0	0.0	0.0
Mirabegron 50 mg	-0.0	-0.0	-0.0	-0.0
Placebo	0.0	0.0	-0.0	-0.0

Intervention	Scores on a scale (Least Squares Mean)
	Week 4 [ N= 354; 346; 335]	Week 8 [N= 325; 321; 323]	Week 12 [N=315; 308; 317]	Final Visit (LOCF) [N= 356; 350; 344]
Mirabegron 100 mg	-16.1	-20.3	-20.7	-20.2
Mirabegron 50 mg	-13.5	-16.0	-17.4	-17.0
Placebo	-9.7	-11.6	-11.3	-10.8

Intervention	participants (Number)
	Not anxious -> Not anxious	Not anxious -> Moderately anxious	Not anxious -> Extremely anxious	Not anxious -> Missing data	Moderately anxious -> Not anxious	Moderately anxious -> Moderately anxious	Moderately anxious -> Extremely anxious	Moderately anxious -> Missing data	Extremely anxious -> Not anxious	Extremely anxious -> Moderately anxious	Extremely anxious -> Extremely anxious	Extremely anxious -> Missing data	Missing data -> Not anxious	Missing data -> Moderately anxious	Missing data -> Extremely anxious	Missing data -> Missing data
Mirabegron 100 mg	250	33	0	1	46	75	0	0	2	2	2	0	1	0	0	0
Mirabegron 50 mg	250	36	1	1	48	71	1	2	2	9	0	0	4	0	0	0
Placebo	239	30	2	4	58	76	7	3	1	5	7	0	1	0	0	0

Intervention	participants (Number)
	No problem -> No problem	No problem -> Some problems	No problem -> Confined to bed	No problem -> Missing data	Some problems -> No problems	Some problems -> Some problems	Some problems -> Confined to bed	Some problems -> Missing data	Confined -> No problems	Confined -> Some problems	Confined -> Confined to bed	Confined -> Missing data	Missing data -> No problems	Missing data -> Some problems	Missing data -> Confined to bed	Missing data -> Missing data
Mirabegron 100 mg	291	24	0	1	41	54	0	0	0	0	0	0	1	0	0	0
Mirabegron 50 mg	304	17	0	2	37	58	0	1	1	0	1	0	3	1	0	0
Placebo	318	15	0	6	41	49	0	1	1	0	0	0	2	0	0	0

Intervention	participants (Number)
	No pain -> No pain	No pain -> Moderate pain	No pain -> Extreme pain	No pain -> Missing data	Moderate pain -> No pain	Moderate pain -> Moderate pain	Moderate pain -> Extreme pain	Moderate pain -> Missing data	Extreme pain -> No pain	Extreme pain -> Moderate pain	Extreme pain -> Extreme pain	Extreme pain -> Missing data	Missing data -> No pain	Missing data -> Moderate pain	Missing data -> Extreme pain	Missing data -> Missing data
Mirabegron 100 mg	204	31	1	1	57	95	8	0	3	5	6	0	1	0	0	0
Mirabegron 50 mg	198	32	1	2	79	84	9	1	2	8	6	0	2	1	0	0
Placebo	201	34	1	3	76	92	3	3	3	7	8	1	1	0	0	0

Intervention	participants (Number)
	No problem -> No problem	No problem -> Some problems	No problem -> Unable to wash or dress myself	No problem -> Missing data	Some problems -> No problems	Some problems -> Some problems	Some problems -> Unable to wash or dress myself	Some problems -> Missing data	Unable to wash or dress myself -> No problems	Unable to wash or dress myself -> Some problems	Unable to wash or dress -> Unable to wash or dress	Unable to wash or dress myself -> Missing data	Missing data -> No problems	Missing data -> Some problems	Missing data -> Unable to wash or dress myself	Missing data -> Missing data
Mirabegron 100 mg	386	6	1	2	8	5	0	0	0	0	0	0	4	0	0	0
Mirabegron 50 mg	392	9	0	3	8	10	0	0	0	0	0	0	3	0	0	0
Placebo	398	10	1	6	7	5	0	1	2	1	0	0	2	0	0	0

mirabegron

Description

Cross-References

Synonyms (68)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (4)

Bioassays (40)

Research

Studies (543)

Market Indicators

Research Demand Index: 113.23

Study Types

Clinical Trials (157)

Trial Overview

Trial Outcomes

Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Total Score

Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Storage Symptom Score

Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)

Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax)

Change From Baseline to End of Treatment in Bladder Voiding Efficiency (BVE)

Safety Assessed by Adverse Events (AEs), Electrocardiogram (ECG), Vital Signs, Physical Exam and Laboratory Tests

Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptom (ICIQ MLUTS) Total Symptom Score

Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptom (ICIQ MLUTS) Total Bother Score

Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Lower Urinary Tract Symptom Quality of Life (ICIQ-LUTSqol) Symptom Score

Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Urgency Episodes With Urgency Severity ≥ 3 Per 24 Hours

Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Lower Urinary Tract Symptom Quality of Life (ICIQ-LUTSqol) Overall Symptom Interference of Life Score

Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Postvoid Residual Volume (PVR)

Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Patient Perception of Bladder Condition (PPBC)

Change From Baseline to End of Treatment in Bladder Contractile Index (BCI)

Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Voided Volume Per Micturition

Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Micturitions Per 24 Hours

Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours

Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Voiding Score

Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Health-related Quality of Life (HRQL) Total Score

Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Level of Urgency

Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Nocturia Episodes Per 24 Hours

Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Pads Used Per 24 Hours

Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Urgency Episodes (Grades 3 or 4) Per 24 Hours

Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Urgency Incontinence Episodes Per 24 Hours

Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Number of Non-study Related Visits to Physician

Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Symptom Bother Score

Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score

Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Mobility Score

Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score

Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Self-care Score

Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score

Change From Baseline to Week 12 and Final Visit in Patient Perception of Bladder Condition (PPBC)

Change From Baseline to Week 12 and Final Visit in Treatment Satisfaction on Visual Analog Scale (TS-VAS)

Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment

Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working

Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment

Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed

Change From Baseline to Week 4, Week 8 and Week 12 in Mean Volume Voided Per Micturition

Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in the European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)

Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours

Change From Baseline to Week 8 and Week 12 in Mean Number of Incontinence Episodes Per 24 Hours

Change From Baseline to Week 8 and Week 12 in Mean Number of Micturitions Per 24 Hours

Percentage of Participants With ≥ 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and the Final Visit

Percentage of Participants With Improvement in Patient Perception of Bladder Condition (PPBC) at Week 12 and Final Visit

Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and the Final Visit

Change From Baseline to End of Treatment (Final Visit) in Mean Number of Micturitions Per 24 Hours

Change From Baseline to Final Visit in Mean Volume Voided Per Micturition

Change From Baseline to Week 4 in Mean Number of Incontinence Episodes Per 24 Hours

Change From Baseline to Week 4 in Mean Number of Micturitions Per 24 Hours

Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score

Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Mobility Score

Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score

Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Self-Care Score

Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score

Change From Baseline to Month 12 and Final Visit in Patient Perception of Bladder Condition (PPBC)

Intervention	participants (Number)
	No problem -> No problem	No problem -> Some problems	No problem -> Unable	No problem -> Missing data	Some problems -> No problems	Some problems -> Some problems	Some problems -> Unable	Some problems -> Missing data	Unable -> No problems	Unable -> Some problems	Unable -> Unable	Unable -> Missing data	Missing data -> No problems	Missing data -> Some problems	Missing data -> Unable	Missing data -> Missing data
Mirabegron 100 mg	287	19	1	1	50	48	2	0	1	0	2	0	1	0	0	0
Mirabegron 50 mg	297	19	1	2	45	50	1	1	0	5	1	0	2	1	0	0
Placebo	303	22	0	6	47	52	0	1	0	1	0	0	1	0	0	0

Intervention	Scores on a scale (Least Squares Mean)
	Week 12 [N=373; 376; 371]	Final Visit (LOCF) [N=392; 388; 377]
Mirabegron 100 mg	-0.8	-0.8
Mirabegron 50 mg	-0.7	-0.7
Placebo	-0.6	-0.5

Intervention	Scores on a scale (Least Squares Mean)
	Week 12 [N= 371; 375; 368]	Final Visit (LOCF) [N= 390; 387; 373]
Mirabegron 100 mg	2.09	2.09
Mirabegron 50 mg	1.57	1.55
Placebo	0.72	0.70

Intervention	percent activity impairment (Mean)
	Week 12 [N= 368; 368; 363]	Final Visit (LOCF) [N= 386; 380; 368]
Mirabegron 100 mg	-10.8	-10.7
Mirabegron 50 mg	-12.9	-12.3
Placebo	-7.5	-6.7

Intervention	percent impairment while working (Mean)
	Week 12 [N= 142; 143; 137]	Final Visit (LOCF) [N= 147; 146; 137]
Mirabegron 100 mg	-8.2	-8.2
Mirabegron 50 mg	-8.5	-8.6
Placebo	-7.1	-6.2

Intervention	percent overall work impairment (Mean)
	Week 12 [ N= 135; 138; 130]	Final Visit (LOCF) [N= 140; 140; 130]
Mirabegron 100 mg	-8.7	-8.7
Mirabegron 50 mg	-8.2	-8.2
Placebo	-7.1	-6.1

Intervention	percent work time missed (Mean)
	Week 12 [N= 136; 138; 131]	Final Visit (LOCF) [N= 141; 140; 131]
Mirabegron 100 mg	-1.3	-1.3
Mirabegron 50 mg	-0.2	-0.2
Placebo	0.03	0.3

Intervention	mL (Least Squares Mean)
	Week 4 [N=433; 421; 409]	Week 8 [N=394; 394; 391]	Week 12 [N=382; 378; 376]
Mirabegron 100 mg	19.2	19.4	18.7
Mirabegron 50 mg	15.2	19.0	19.7
Placebo	7.1	5.4	7.2

Intervention	Scores on a scale (Mean)
	Week 4 [N= 413; 406; 396]	Week 8 [N= 385; 385; 387]	Week 12 [N= 377; 369; 378]	Final Visit (LOCF) [N=424; 417; 410]
Mirabegron 100 mg	0.52	2.34	3.89	3.52
Mirabegron 50 mg	0.85	2.17	3.60	3.04
Placebo	-0.57	1.15	1.92	1.46

Intervention	Incontinence episodes (Least Squares Mean)
	Week 8 [N= 296; 288; 279]	Week 12 [N=283; 278; 267]
Mirabegron 100 mg	-1.61	-1.60
Mirabegron 50 mg	-1.32	-1.45
Placebo	-0.93	-1.13